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Abstract
Advances in cancer therapies continue to be improved, yet cancer continues to be one of the
deadliest diseases in the world. Harnessing the power of the body’s immune system to attack
cancer is a promising strategy that can further improve therapies for neoplastic diseases. As part
of this strategy, cytokines such as interleukin (IL) 2 and interferon α are currently accepted
cancer treatments, and other cytokines such as IL12 and GM-CSF also show potential as new
treatments. Clinical trials with these cytokines have shown less than acceptable therapeutic
efficacy and toxicities, but tumor-targeting motifs can improve these effects. Both antibodies and
peptides specific for tumor antigens have been used in recombinant protein and gene therapy
systems to increase the intratumoral cytokine accumulation and decrease systemic toxicities.
Still, these treatments have not been capable of overcoming the obstacles for clinical acceptance.
The hypothesis tested in this dissertation is that inserting tumor-targeting peptide coding
sequences into IL12 plasmid DNA will create a novel systemic gene therapy approach which
will increase the antitumor efficacy and decrease toxicity for cancer treatments. To accomplish
this goal, a reporter gene mediated screening strategy was developed to identify a peptide which
can target multiple tumor models. While preparing this method, it was discovered that these
peptides can have a strong effect on the activity of the conjugated reporter gene. Once this
strategy was finalized, the peptide VNTANST was found to increase the intratumoral
accumulation of the reporter gene in five tumor models including a human xenogeneic model.
The VNTANST coding sequence was then inserted into an IL12 plasmid to examine the
antitumor efficacy. In breast adenocarcinoma, squamous cell carcinoma, and colon carcinoma
models, VNTANST-IL12 plasmid DNA treatments distal from the tumor site increased tumor
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inhibition and, in two models, prolonged survival. Also, these treatments reduced the
development of metastatic lung tumors in a spontaneous metastatic model. As expected, these
tumor-targeted IL12 treatments decreased the level of liver toxicity compared to wild-type
treatments. The receptor for VNTANST was identified as vimentin, which is a potentially
powerful target for human cancers.
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Chapter 1
Passive and Active Tumor Homing Cytokine Therapy*

*Reprinted with permission from Springer Science + Business Media
1

Introduction
In 2008 approximately 565,500 people will die from and more than 2 million people will
be diagnosed with cancer in America alone. While continued progress in conventional therapies
such as surgery, radiation, and chemotherapy is being maintained and the 5-year survival of
cancer patients is steadily increasing for most types, cancer is still one of the leading causes of
death in America, second only to cardiovascular disease [1]. Most cancer deaths are attributed to
metastatic disease which can be distributed throughout the body [2] and residual tumors which
remain after treatment with conventional therapies [3]. Thus, new cancer treatment strategies
must be able to destroy not only the primary tumors but also all of the metastatic or residual
tumor cells which remain after conventional treatments. One of the most promising strategies to
accomplish this feat is directly targeting immunostimulatory agents to tumor cells or tumor
microenvironments.
The ability of the immune system to attack tumor cells was first hypothesized by Paul
Erlich in 1909, but the discovery of cytokines, intracellular signaling proteins produced by
immune cells, and their ability to increase the immune response towards cancer really boosted
the study of immunomodulation for cancer therapy [4]. Among these cytokines were Tumor
Necrosis Factor (TNF)α [5], Interleukin (IL)2 [6], and IL12 [7]. Interestingly, the biological
properties of these cytokines vary tremendously yet all have since shown potential for treating
malignancies. For instance, TNFα has direct cytotoxic effects against tumor cells as well as
activating antitumor immune responses [8], IL2 induces proliferation of B, T, and NK cells [9],
and IL12 induces Interferon (IFN) γ in T and NK cells [10]. While these and other cytokines are
pleiotropic, many have overlapping functions such as the ability of IL2 and IL12 to enhance the
cytotoxicity of Natural Killer (NK) and activated T cells [11] and synergistically upregulating
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the other’s receptors via independent signaling pathways [12]. In fact, very quickly after the IL2
gene was purified in substantial amounts clinical trials in cancer patients began [13, 14].With the
continued elucidation of these potential antitumor qualities, several cytokines have been and
continue to be clinically evaluated for the treatment of many types of cancer.
Unfortunately, several clinical trials implementing systemic delivery of recombinant
cytokines for the treatment of cancer failed to produce positive results and produced severe
toxicities. For early IL2 clinical trials the only benefits were seen in patients with renal cell
carcinoma (RCC) and malignant melanoma. While only a select few patients benefited from the
treatments, toxicities ranging from the severe, such as hypotension, vascular leak, and respiratory
insufficiencies, to the problematic, like nausea, emesis, diarrhea, etc., limited the levels of
cytokines that could be delivered and, therefore, the antitumor effects [4]. Similar results were
seen in clinical studies using systemic delivery of recombinant IL12 and TNFα. So, the next
steps to overcome the barriers of systemic cytokine therapies were locoregional delivery of the
cytokines and combinational treatment regimens. Unfortunately, the benefits of these treatment
strategies have continued to be undermined by the toxicity [4, 8, 10, 12]. Despite the low
response rates and high potential for toxicity, IL2 is clinically approved in the United States,
Canada, and the European Union for the treatment of RCC [4].
Nonetheless, the potential benefits of cytokine therapy for the treatment of cancer are
present but there are still several obstacles that need to be overcome. With systemic cytokine
treatments, the level of cytokine is increased systemically which leads to most of the toxicities
and even death in some cases. Also, the increase in cytokine level was generally not high enough
at the target area (i.e. tumor site) to elicit an immune response capable of creating a therapeutic
benefit. Another problem with the treatments was the rapid clearance of the cytokine through the
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body’s normal excretory and biotransformation systems. Even with locoregional administrations
the minimal level of cytokine concentrations for therapeutic benefits was hard to maintain as
well as the fact that most tumors are not available for noninvasive administrations [4, 8, 10, 12].
So, there is a need for treatments that can reach sites distal from the site of administration, reach
an immunologically active concentration of the cytokine, and maintain that concentration long
enough to induce a therapeutic response.
One such administration technique that could improve the efficacy of cytokine treatments
is gene therapy. Local delivery of cytokine-encoding genes is capable of producing therapeutic
levels of cytokines at the site of delivery with only slight increases in systemic cytokine levels.
Also, the local concentration of cytokines will persist so the immune system can be properly
activated. Furthermore, for difficult-to-reach sites of administrations, the frequency of treatment
is lower so the therapy is less invasive. Toward this purpose, several types of vectors including
multiple viral and non-viral vectors have been tested in animal models as well as clinical trials
[2, 4, 15, 16]. There is still much debate about which vector is the best for the treatment of
cancer in humans because they all have varying advantages and disadvantages. Several cytokine
genes in various vectors have already been investigated via systemic and locoregional
administration in preclinical and clinical trials including IL2, IL12, TNFα, IFNα, and many
more. Another method for local cytokine delivery is adoptive transfer of cells that have been
transfected with cytokine producing genes. These cells can be delivered by either intratumoral
(i.t.) or peritumoral (p.t.) injection, where they will then produce and secrete the cytokines in the
tumor microenvironment [17-20]. Regrettably, most of these cytokine treatment approaches with
a few exceptions have yet to successfully overcome enough barriers to meet the requirements
necessary to become clinically approved treatments for cancer [4, 15].
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A very promising solution to the aforementioned obstacles for cytokine therapy of cancer
is targeted delivery of the cytokines to the tumor and tumor microenvironment. For the purpose
of this review, targeting entails any method that enhances the delivery, retention, and biological
activity of the cytokines at the tumor site. Toward this goal, researchers have developed a wide
array of strategies ranging from the passive targeting via the enhanced permeability and retention
effect of tumors to the active targeting of tumor and tumor microenvironment antigens. This
review will focus on the development, action, progress, and future directions of targeting
cytokines to tumor sites for immunomodulatory treatments.
Passive Targeting with Poly(Ethylene Glycol)
First described in 1986, tumor environments are characterized by fenestrated vasculature
and poor lymphatic drainage [21]. Now termed enhanced permeability and retention (EPR), this
tumor-specific trait can be exploited to accumulate high concentrations of systemically delivered
treatments. In brief, intravenously delivered agents collect in the tumor tissue by passively
transversing large gaps between endothelial cells in the tumor vasculature. Once present in the
tumor tissue, these agents remain due to the poor drainage of the lymphatics in the tissue;
therefore, the concentration of these agents continues to increase. Most systems that attempt to
exploit the EPR effect are nanoparticle colloidal drug carrier systems which consist of repeating
elements conjugated to therapeutic modalities. When these systems are introduced into the blood
circulation, they are readily incapacitated by opsonization and then rapidly removed by the
mononuclear phagocytic system (MPS) and the reticulo-endothelial system (RES), so the
nanoparticels are not present in circulation long enough to utilize the EPR and create an
antitumor effect [21, 22].
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Several investigators have worked to develop new stealth nanoparticles that can avoid
these systems. Several stealth particles were discovered including poly(acrylamide),
polysaccharides, and poly(vinyl alcohol). The most widely used and successful technique is the
addition of poly(ethylene glycol) (PEG) units onto the surface of particles which is known as
PEGylation. PEG has a structure of HO-(CH2CH2O)n-CH2CH2-OH. This structure encompasses
a chemically inert polyether backbone. Another key component of PEG is the terminal hydroxyl
groups which can be used for conjugation to an extensive list of agents. In vivo, these stealth
nanoparticles have longer half-lives in circulation which leads to an increased invasion of tumor
vasculature and accumulation in the tumor site. This stealth characteristic of PEG is determined
by several different factors including particle size and surface characteristics. Optimization of
these factors has led to the increased efficacy of cytokine-nanoparticle conjugates [23].
IFNα has long been known to be critical in antitumor therapies in addition to its direct
antitumor effects [24]. Several clinical trials have shown the potential for IFNα to be used as a
treatment for tumors, but the effective dose is hard to reach due to toxicities of systemic
treatment. Also, the short elimination half-life (T1/2) of IFNα necessitates daily administrations to
see any therapeutic effect [25]. PEGylation of IFNα elongates its T1/2 in humans from 4 to 16 h
for unmodified IFNα to 61 to 100 h. Likewise, the absorption T1/2 increased from 2.3 h to
approximately 50 h. Several other factors are increased with the PEGylation of IFNα making the
treatment of cancer with IFNα more plausible [26].
Indeed, one of the first phase I clinical trials using PEGylated IFNα-2B (one form of
IFNα) (PEGIFNα-2B) in patients with chronic myeloid leukemia (CML) showed a dramatic
increase in the efficacy of treatments. In this study, the MTD of PEGIFNα-2B was defined as 7.5
to 9 μg/kg weekly. This dose level given weekly is equivalent to 3 times the dose level of IFNα-
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2B in previous CML studies with no increase in toxicities. Furthermore, 53% of patients who
were suffering from active disease at the start of the trial showed a therapeutic response. Of the
27 patients in the study who had failed previous IFNα therapy, 13 had a favorable response to
this treatment. Also, this study used subcutaneous (s.c.) administrations and the PEGIFNα-2B
was readily absorbed with increasing serum concentrations through week 1, but not by week 4.
This early clinical study showed the safety, ease of administration, and efficacy of treatment with
PEGIFNα-2B [25].
Preclinical and clinical studies with different types of PEGylation conjugated to various
cytokines has steadily continued; therefore, the quality of PEG used to modify cytokines has
improved. One of the best modifications to PEGylation of cytokines was the creation of
poly(methoxypolyethyleneglycol-cyanoacrylate-co-n-hexadecyl cyanoacrylate) nanoparticles
(PEG-PHDCA). This new formulation is a more rapidly degradable copolymer with higher
stealth capabilities. Similar to the original PEG-IFNα studies, PEG-PHDCA conjugated to TNFα
increased the Th of TNFα in the blood circulation. Also, accumulation at the tumor site was
increased at 6 h after intravenous injection [27]. So, the PEG-PHDCA increased the length of
activity for TNFα, but the characteristics that created this increase were not well understood.
The study of how these characteristics and the formulation of the nanoparticles helped to
increase their tumor-targeting capabilities. First, studies to analyze the effects of molecular
weight and particle size of surface modifications of PEG-PHDCA conjugated to TNFα resulted
in optimized parameters for increased circulation time and tumor accumulation. These studies
revealed that nanoparticles with smaller PHDCA particle sizes (~80 nm) with larger molecular
weights (5 kD) decreased serum protein adsorption which results in decreased phagocytosis,
increased circulation time, and higher accumulation in the tumor compared to other tissues. The
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smaller particle size allows a higher density of MePEG chains which increases the interaction
between the particles and water molecules which prevents the adsorption of serum proteins [23,
28].
Another use of PEG for targeting cytokines to tumors is conjugation to the shell of virus
vectors loaded with cytokine-coding genes. Since one of the major limits to viral gene-therapy is
the antibody response to the vectors, PEGylation of the vectors can help reduce detection by the
the humoral immune system. Indeed, intravenous injection of PEGylated adenovirus vectors
(PEG-Ad) in mouse models results in reduced CTL production and elongated viral gene
expression from 4 to 42 d [29]. Furthermore, PEG-Ad encoding TNFα (PEG-Ad-TNF) has
several benefits over unmodified vectors (Ad-TNF). First, the T1/2 of PEG-Ad-TNF was 12-fold
longer than the unmodified. Second, PEG-Ad-TNF gene expression in the tumor and liver tissue
was 35-fold higher and 20-fold lower than Ad-TNF, respectively. The PEG-Ad-TNF also
showed increased antitumor activity compare to Ad-TNF. These results show that there is
potential for treating tumors with systemic administration of PEG-Ad loaded with cytokine genes
[30].
Exploiting the EPR effect for targeting cytokines to tumors can improve the efficacy
while reducing the toxicity. This effect is caused by the nature of solid tumors and their effects
on the physiologic conditions of the tumor environment. Adding PEG and different variations of
PEG can increase the circulation time of cytokines allowing for increased concentrations in the
tumor environment and decreased concentrations in toxicity causing tissues such as the liver.
While these effects can be seen in solid tumors, better modalities to exploit more specific tumorassociated characteristics for targeting the cytokines in the tumor environment can further
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increase the effectiveness and decrease the toxicity of these treatment strategies for tumor
therapy.
Active Ligand Targeting with Tumor-homing Peptides
In addition to the EPR effect, tumors have many other unique attributes which can be
exploited for targeting cytokines. To exploit these traits, several active targeting strategies have
been developed such as peptides that home to tumor environments. With the advent of in vivo
biopanning with peptide phage display technology, vast amounts of peptides can be expressed on
the surface of phage and then analyzed for their ability to bind to ligands in the different tissue
types [31]. Using this technique, several peptides have been isolated, and new ones continue to
be discovered, that preferentially target tumors [32]. Of these tumor-targeting peptides, the most
widely studied and most successful peptides do not only target the tumors themselves but also
target motifs that are expressed due to unique qualities of the tumor environment. Specifically,
these peptides target proteins that are upregulated in tumor vasculature and lymphatic vessels
[33].
Peptides that contain the amino acid sequence Arg-Gly-Asp (RGD) were one of the first
targeted peptides discovered via biopanning. These peptides target integrins that are upregulated
during angiogenesis but bind most specifically to the integrins αvβ3 and αvβ5. Along with their
ability to bind to these integrins, RGD peptides are also capable of internalizing into the cells,
causing cell death, and interrupting the development of more vasculature. There are several
different RGD peptide variants, including ACDCRGDCFCG (RGD4C), which have different
beneficial abilities [33, 34]. By using knockout mice to isolate the effects of the RGD4C peptide,
it was shown that RGD4C has antiangiogenic effects. Using multiple angiogenesis assays in
these knockout strains, RGD4C repeatedly demonstrated antiangiogenic capabilities [35]. While
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these peptides have beneficial properties in addition to their targeting abilities, it is their
interactions with integrins which have been used for targeting, imaging, and treating tumors in
preclinical models [33-39].
Among these techniques, conjugating RGD sequences to cytokines has shown to increase
the therapeutic effect compared to the wild-type (wt) cytokines. RGD-cytokine conjugates can be
produced by expression of the fusion protein by recombinant DNA technology or chemical
coupling of the purified peptide to purified cytokines. By these methods, several fusions of
different RGD peptides with murine and human cytokines have been created, and these fusions
have been examined in vitro and in vivo. Most RGD-cytokine conjugates maintain both the
binding specificity of the RGD peptide and the biological activity of the conjugated cytokines
[36, 37, 39].
One of the most widely studied RGD-cytokine conjugates are those using TNFα. Several
different groups have analyzed the RGD binding ability of these conjugates in vitro, and they
determined that conjugating RGD peptides does not affect the affinity of the peptide for its
receptors [36, 37, 39]. Likewise, the activity of the conjugated TNFα was not lower than the wt
cytokine as demonstrated through fibroblast cell viability assays [37, 39]; however, cell viability
studies using a cell line that expresses the receptor intregrins specific for RGD showed that the
conjugated TNFα does have increased toxicity to these cells. Also, incubating the cells with
excess RGD peptide prior to addition of the TNFα and RGD-TNFα decreased the activity of the
RGD-TNFα and not wt TNFα. So, the increased activity is due to the binding of the RGD-TNFα
to its receptors on the cell surface. Similar results were found by exploiting another attribute of
TNFα: ICAM-1 induction. FACS analysis revealed that RGD-TNFα increased the expression of
ICAM-1 more than TNFα, and preincubation with free RGD peptide reduced the ICAM-1
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expression level to that of the wt TNFα while not reducing the level of ICAM-1 induced by the
TNFα [36]. The results from these in vitro studies demonstrate the potential for using RGDTNFα conjugates in preclinical models.
Indeed, different groups have demonstrated that RGD-TNFα does have increased
antitumor activities in vivo. Since TNFα is used to increase the efficacy of chemotherapeutic
treatments, one group studied the effect of using RGD4C-TNFα in conjunction with melphalan, a
commonly used chemotherapeutic agent. They found that a single treatment of RGD4C-mTNFα
(0.3 ng i.p.) when administered in conjunction with one treatment of melphalan (50 ng i.p.) was
able to reduce tumor growth in a syngeneic RMA lymphoma model when administration of
either agent alone induced no antitumor effects. Also, while the addition of RGD4C-TNFα to the
chemotherapeutic treatment increased antitumor efficacy, there was no corresponding change in
animal weight revealing that there is no increase in toxicity with the combinatorial treatments
[36]. More recently, another group has shown that treatments of RGD4C conjugated to human
TNFα (RGD4C-hTNFα) can improve the antitumor efficacy of hTNFα in a nude mouse model.
In these reports, nude mice bearing xenogenic MDA-MB-435 tumors were treated with 5
consecutive daily i.v. injections of saline, hTNFα, or RGD4C-hTNFα (0.25 mg/kg). Compared to
the saline treated group, treatment with hTNFα and RGD4C-hTNFα resulted in tumor volume
reductions of 24% and 72%, respectively, by 15 d after treatment. The investigators also
monitored animal weight, and there was no difference among the groups throughout the
experiment. Additionally, ex vivo staining for CD31 and TUNEL revealed that the RGD4ChTNFα treatments resulted in selective cytolysis of αvβ3-positive tumor cells and tumor vessels
while the saline and hTNFα treatments did not cause any integrin dependant cytolysis [38].
These in vivo results continue to show the potential for using RGD peptides to increase the

11

antitumor effect of TNFα while reducing the toxicity which is normally seen in TNFα
treatments.
RGD peptides have also been shown to improve the antitumor efficacy of other
cytokines. Similar to RGD4C-TNFα in vitro studies, the RGD4C-IL12 conjugate mrIL12vp
binds to the αvβ3-positive cell line M21 (human melanoma) and not to the αvβ3-negative cell line
Saos-2 (human osteosarcoma) while the nontargeted mrIL12 did not bind to either cell line.
Furthermore, in vivo toxicity studies with i.p. injections of 0.025 to 0.5 µg/d of mrIL12 resulted
in readily observable toxicities such as loss of appetite, weight loss, trouble breathing, and even
sudden death after seven days, and comparable levels of mrIL12vp did not cause any such
toxicity. Also, when NSX2-tumor-bearing mice were treated with PBS, mrIL12, or mrIL12vp
continuously for 3 weeks (1 µg/d), there was a nearly two-fold reduction in tumor volume with
the targeted therapy compared to both PBS and nontargeted IL12 therapies. So, RGD4C can also
increase the efficacy of IL12 for treating tumors while simultaneously decreasing the toxic
effects normally seen with IL12 treatments [35]. All of the aforementioned experiments
employing conjugates of RGD peptides and cytokines show that the RGD-integrin interactions
can be exploited to enhance the antitumor efficacy and reduce the toxicity of cytokine tumor
therapies.
Another set of peptides that target tumor environments are peptides containing the amino
acid sequence Asn-Gly-Arg (NGR). Similar to RGD peptides, NGR peptides were first identified
via in vivo biopanning [31] and preferentially bind to a ligand, aminopeptidase N (CD13), which
is upregulated on tumor vessels during angiogenesis [40]. CD13 is also found in other tissues
such as kidney and myeloid cells, but the NGR peptides do not bind to CD13 found in normal
tissues [41]. While there are several different NGR-containing sequences that have been used to
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target to tumor environments, disulfide-bridged cyclic NGR peptides (CNGRC) show an
increased affinity for CD13 and increased antitumor activity, greater than 10-fold higher, when
coupled to TNFα compared to a linear NGR peptide (GNGRG) [42]. So, the cyclic-NGR
peptides have a lot of potential to be used as tumor targeting vehicles for cytokines.
After the discovery that NGR peptides do indeed target an angiogenesis marker in tumor
vasculature, the natural next step was to investigate its ability to facilitate the delivery of
antitumor therapies. To this end, NGR was first coupled the murine TNFα (NGR-TNFα) and
characterized via in vitro cytotoxicity assays. These experiments using L-M mouse fibroblast
cells revealed that coupling the NGR peptides to murine TNFα did not affect the folding,
oligomerization, or binding to TNFα receptors. After these proof-of-concept experiments, NGRTNFα was administered to C57/Bl6 mice bearing syngeneic RMA-T lymphoma tumors. The
LD50 values of TNFα and NGR-TNFα were 60 μg and 45 μg, respectively, which are not very
different; however, the antitumor effects were drastically different. Impressively, 1 μg of NGRTNFα delayed tumor growth better than 27 μg of TNFα 14 days after a single i.p. administration
10 days after tumor inoculation. Also, some mice treated with less than the LD50 of NGR-TNFα
were completed cured of tumors while no mice treated with any amount of TNFα were
completely cured of tumors. The body weights of mice from these experiments were monitored
to identify the difference in toxicity from NGR-TNFα compared to TNFα. The efficacy:toxicity
ratio of NGR-TNFα was 14 times higher than those of TNFα. Similar experiments were
performed using syngeneic B16F1 tumors to analyze the effects of multiple treatments. With
treatments at days 11, 17, and 19 after tumor cell inoculation, NGR-TNFα was 12 to 15 times
more effective than the same doses of TNFα while the toxicities were comparable [43]. These
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studies reveal the increased antitumor activity and decreased toxicity of NGR-TNFα vs. TNFα
which shows the potential for NGR-TNFα in the treatment of tumors.
NGR-TNFα was evaluated also for its ability to enhance the antitumor efficacy of
chemotherapeutic agents. Similar to RGD-TNFα, a single administration of subnanogram levels
of NGR-TNFα combined with a single dose of melphalan (50 μg) creates a synergistic decrease
in tumor volume with no corresponding increase in toxicity as determined by animal weights.
Interestingly, only 0.1 ng of NGR-TNFα is needed to see a significant reduction in tumor volume
while no difference is seen in tumor volumes below 0.3 ng of RGD4C-TNFα [36]. More recent
studies have shown that pretreatment with NGR-TNFα as opposed to simultaneous treatment
greatly increases the efficacy of the chemotherapeutic agents. In several different tumor models
and with different chemotherapeutic drugs, a pretreatment with 0.1 μg NGR-TNFα increased the
efficacy of the drugs without increasing the toxicity seen with any of the drugs or NGR-TNFα
alone. Notably, the increase in efficacy of each drug in combination with NGR-TNFα was
different depending on the tumor model used [44, 45]. Interestingly, NGR-TNFα does not
increase the cytotoxicity of doxorubicin in in vitro cytotoxicity assays using the prostate cancer
tumor cell line TRAMP-C1, but the in vivo antitumor effect of doxorubicin with NGR-TNFα was
significantly increased. This observation demonstrates that NGR-TNFα does not directly
increase the cytotoxicity of doxorubicin but instead primes the tumor environment to increase the
effect of the doxorubicin on tumor growth [46]. In addition to the direct antitumor activity of
NGR-TNFα, it can also synergistically increase the efficacy of chemotherapeutic drugs.
Recent studies have shown that NGR also increases the antitumor efficacy of the human
cytokine IFNα2a by targeting to the tumor environment. In vitro studies of EC migration and
tube formation using IFNα2a and the NGR-IFNα2a conjugate revealed that the conjugate had
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consistently increased antiangiogenic effects at all tested concentrations as determined by a
reduction of tube formation by HUVEC in matrigel. Similarly, treatment with NGR-IFNα2a to
HUVEC induced with bFGF reduced the ability of the cells to migrate through matrigel more
than IFNα2a. Also, in two different xynogeneic tumor models in nude mice daily i.p. treatments
of NGR-IFNα inhibited tumor growth at levels comparable to those seen with 2- to 5-fold higher
doses of IFNα2a. At all treatment doses, no toxicities were observed with either formulation
[47]. Further toxicity studies were performed on mice, rats, and monkeys using
pharmacologically active doses. Following single doses ranging from 50 to 674 times higher than
the clinical dose for adults resulted in no toxicities evidenced by no abnormalities in general
signs and animal weights for all species as well as food consumption, urinalysis, hematological
examinations, and blood biochemical examinations in monkeys. For repeated-dose studies, rats
were administered daily i.m. injections with 1.5x106, 4.5x106, or 1.25x107 U/kg for 90 days and
monkeys were given 7.5x105, 2.25x106, or 6.75x106 U/kg for 47 days. In rats, there were no
changes in body weights, food intake, or general health and activity. There were some minor
changes in some hematological and clinical chemistry parameters, but all levels returned to
normal levels after the administrations. The results in the monkey studies were similar with no
deaths occurring during the treatments and most of the clinical and pathology changes returned
to normal after the administrations were discontinued [48]. These preclinical efficacy and
toxicity data indicate that targeting IFNα2a to tumors using NGR is a very plausible safe and
effective treatment for malignant diseases in humans.
Effort continues to be made to discover more peptides that can target tumor environments
and to improve the targeting abilities of the peptides. The secret to improving these peptides may
not only be based on discovering new peptides [32] but also on improving the current peptide
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modalities. To such an end, modifying peptides to increase the amount of ligand interactions they
can utilize in the tumor environment would be extremely beneficial. Recently, a shortened
version of RGD4C, CDGRC, when fused to murine IFNα and delivered via i.m., i.t., or i.d.
injections of plasmid DNA followed by electroporation maintains its ability to anchor in tumor
environments and produce antitumor immune responses. This peptide sequence shares homology
with NGR peptides as well as RGD peptides so its array of potential ligands is increased to
create better homing abilities. Additionally, it has a shorter amino acid sequence than RGD4C so
it is less likely to cause a humoral response to the recombinant fusion protein [49]. Further
modifications of these peptides will continue to improve the efficacy of peptide-cytokine
treatments for malignancies and possibly propel them into clinical settings.
An alternative method to reduce toxicity and increase efficacy of cytokines is to deliver
cytokine genes to tumors. Virus vectors have been studied extensively to deliver genes to various
tissue types. Modifying the tropism of the viral vectors to preferentially transduce cells in the
tumor or tumor environment would help to sequester the effects of the cytokines and minimize
systemic toxicity. To accomplish this goal, viruses armed with cytokine genes are modified to
express tumor-targeted peptides on the capsid fibers and home to the tumor vasculature to deliver
their payloads. To date, viral vectors have been successfully modified with RGD peptides for the
delivery of various genes to the tumor environment with high success [50]. So, it appears to be a
potential strategy for the delivery of cytokine genes to the tumor environment.
One of the first viral vectors used to attempt this feat were adenovirus modified to
express RGD on the capsid fiber (AdRGD). These vectors were much more efficient at
transducing melanoma cells both in vitro and in vivo. Also, i.t. injections of these vectors loaded
with TNFα-coding DNA (AdRGD-TNFα) resulted in more hemorrhagic necrosis and inhibition
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of tumor growth compared to injection of the conventional vector loaded with TNFα genes.
However, the TNFα produced from the transduced cells would leak into the circulation resulting
in typical TNFα-induced toxicity [51, 52]. Similarly, i.t. injections of AdRGD loaded with IL12
(AdRGD-IL12) resulted in increased transduction of melanoma cells in vitro, and in a syngeneic
melanoma model tumor reduction compared to conventional IL12 loaded vector at a dose level a
magnitude of order less than the non-targeted vector. Different from AdRGD-TNFα, there were
no toxic side effects at therapeutic doses, but loss of body weight was seen with doses that were
high enough to almost completely reduce tumor volume. Furthermore, combinations of AdRGDTNFα and AdRGD-IL12 resulted in complete tumor regression in all treated mice and there were
no detectable cytokine levels in the serum [53]. Although these results are exciting for cytokineloaded-viral vectors to transduce tumor cells, these data do not show any tumor-targeting of the
vectors, but further modifications of the vector capsid fibers as well as the cytokine genes will
increase the effectiveness of the vectors and allow them to be used for systemic delivery of
tumor-targeted cytokine viral vectors.
Active Targeting with Tumor-targeted Antibodies
By far the most investigated method to target cytokines to tumors is the fusion of
antibodies to cytokines to create immunocytokines. Similar to the peptide-cytokine fusions, these
immunocytokines actively target antigens on the tumor cells or in the tumor microenvironment
and enhance the direct antitumor effects of the cytokines or activate an antitumor immune
response against the tumors. On the other hand, antibodies can be developed to specific antigens
in the tumor environment whereas most tumor-targeted peptides are derived from in vivo
biopanning so the ligand is not necessarily known. Also, several factors hamper the ability of
antibodies to successfully be used to improve therapies. First, they are larger molecules with a
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full IgG antibody having a molecular weight of approximately 150 kDa. Second, the original
antibodies used for therapeutic purposes were created by murine hybridoma technology so the Fc
fragments were not fully compatible with the human immune system. Lastly, because they
originated from murine origins, the antibodies elicit an immune response against the antibodies
themselves which in turns reduces the therapeutic effect. For these reasons, the antibodies for
therapeutics had to be modified to have any potential to be successful in humans [54, 55].
Several different approaches have been used to overcome these initial problems for using
antibodies in therapeutic settings, and these approaches differ depending on what the antibody is
used for in the therapy. For most cytokine-antibody conjugate therapies the only region of the
antibody that needs to be functioning properly is the variable region. So, removal of the Fc
fragment can reduce the size and therefore the immunogenicity of the antibody while
maintaining its ability to bind to a specific antigen; however, the resulting fragment is still of
murine origin and still immunogenic. Other modifications of antibodies create chimeric
antibodies which are created by combining human portions of antibodies to murine variable
regions to reduce the immunogenicity [54, 55]. Regardless of which derivative of an antibody is
used, the main goal remains to maintain the specificity of the antibody and the
immunomodulatory effects of the cytokine to get the highest antitumor response with the lowest
possible toxic side effects. To date, tumor specific antibodies have been generated for a vast
array of tumor environment specific ligands, and these antibodies have been conjugated to a vast
array of cytokines.
As in peptide-cytokine therapies, immunocytokines specific for changes specific in tumor
vasculature have proven highly successful. One of the first antigens for these immunocytokines
utilized the recombinant human single chain antibody L19 which is specific for the domain B
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isoform of fibronectin. In addition to being found only in tissue undergoing angiogenesis such as
tumors and the endometrium, an interesting characteristic of this isoform is that the amino acid
sequence is identical in mouse, rat, rabbit, dogs, humans, and several other mammals; therefore,
the specificity of L19 is consistent in all these species [56]. L19 conjugated to IL2 (L19-IL2) was
the first L19 immunocytokine used to for biodistribution and antitumor studies in mice [57].
These first studies found that the L19-IL2 conjugate did indeed target the tumor
neovasculature and increased the antitumor effects of IL2. Radiolabeled L19-IL2 and the
nonspecific conjugate D1.3-IL2 were i.v. administered to nude mice bearing F9 teratocarcinoma
tumors. After 24 hours, the tumor:blood ratio of the L19-IL2 was 33 whereas the D1.3-IL2 was
less than one. Also, microautoradiography showed that the L19-IL2 accumulated around the
tumor vasculature in a similar manner to L19 alone proving that the immunocytokine has similar
binding affinity for its antigen. They also analyzed the antitumor effects in several tumor cell
lines in both syngeneic and xyngeneic models. In all models tested, tumor growth was
significantly reduced with treatment of L19-IL2 compared to D1.3-IL2 and saline treated groups.
In addition to a reduction in tumor volume, increases in tumor-infiltrating lymphocytes and
necrotic area as well as reduction in the level of mitoses were seen with the L19-IL2 treatments.
Also, treatment with a mixture of non-conjugated IL2 and L19 did not show any significant
increases in any of the above mentioned antitumor immune responses [57]. This first study of an
L19-cytokine fusion therapy led the way for several other cytokine conjugates.
L19 was then fused to IL12 to improve the efficacy and reduce the toxicity of the
cytokine treatment for malignancies. In the recombinant L19-IL12 protein the p35 and p40
subunits were fused with a linker to maintain the proper folding of the heterodimer which was
then attached to the N-terminus of L19. As in L19-IL2, this formulation retained the in vitro
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bioactivity of the cytokine and the in vivo biodistribution of the antibody. To determine the
antitumor activity, two syngeneic tumor models, C51 colon adenocarcinoma and F9
teratocarcinoma, were implanted into Balb/c and 129Sv mice, respectively, and then treated with
2.5 μg of L19-IL12, HyHEL10-IL12 (a non-specific antibody fusion), or saline every 48 h
starting 4 days after tumor implantation. Throughout the treatments tumor volume and animal
weights were noted. In both tumor models, tumor growth was drastically reduced with L19-IL12
treatment with at least a 4-fold decrease in tumor volume on the last day. Other signs that reveal
the increased antitumor effects of L19-IL12 included increased tumor infiltration of immune
cells and increased levels of IFNγ in the tumor and serum which were not seen in either of the
control groups. However, in both models there were signs of IL12 induced hepatotoxicity as well
as antibody production against the components of both fusion antibodies. When compared to
treatment with IL12, the L19-IL12 treatments performed better than wt IL12 even at dose levels
as low as 20 times less than the wt cytokine. Also, even when treatments were started as late as 7
days after tumor inoculation there was an 82% reduction in lung metastases compared to saline
treated groups [56]. These results are very promising for L19-IL12 to be used in clinical settings.
Several other L19-cytokine conjugates have been created and studied including those
with IL15, GM-CSF [58], IFNγ [59], and TNFα [60, 61] further proving the potential for
immunocytokines in cancer therapy. In addition, antibodies with different specificities have been
created and tested for their ability to target cytokines to tumor environments. Antigens for these
cytokines include EGF receptor (ch225) [62, 63], ganglioside GD2 [62, 64-66], HER2 [67, 68],
KSA [9, 69], and many more [54]. However, continual improvement in the design of
immunocytokines is needed to develop clinically applicable formulations as evidenced by the
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IL12 induced hepatotoxicity described in the L19-IL12 study above. For these reasons, different
derivations of immunocytokines have been created and studied.
One subsequent investigation involved the therapeutic potential of two new L19-IL12
derivatives. The first is a disulfuide linked homodimer composed of two L19-IL12
immunocytokines [IL12-SIP(L19)], and the other is a single IL12 with a single-chain L19
component linked to each subunit of IL12 (L19-IL12-L19). The biodistribution pattern of IL12SIP(L19) was very similar to L19-IL12 with tumor uptake of less than 1% of the initial dose,
tumor:organ accumulation ratios of approximately 5:1, and high levels of liver uptake; however,
L19-IL12-L19 exhibited a much improved pattern with 19% and 9% tumor uptake at 4 and 24 h,
respectively, and tumor:organ ratios of approximately 10:1 to 20:1 at 24 h. Also, L19-IL12-L19
performed comparably to wt IL12 and L19-IL12 in lymphocyte proliferation assays. Single in
vivo injections up to 80 µg did not cause any weight loss greater than 5%. Antitumor efficacy
studies revealed that indeed the L19-IL12-L19 is the superior agent. Three separate experiments
with a single dose of 20 µg, 4 doses every 3 days of 5 µg, or 3 doses every three days of 20 µg
and 40 µg revealed that IL12-(SIP)L19 retarded tumor growth and extended survival time more
than the group treated with saline, and L19-IL12-L19 was even more effective than doses at and
half of the IL12 molar equivalent of IL12-(SIP)L19 [70]. These results show that modification of
antibodies can increase the performance of immunocytokines for cancer therapies.
Since it has been proved that immunocytokines and modifying the antibody regions of
immunocytokines can increase the therapeutic efficacies of cytokines for tumor therapies, further
avenues to create stronger therapies are continuing to be examined. One such method is using
combinations of immunocytokines to create synergistic therapeutic responses. Several
combinatorial cytokine therapies using recombinant wt cytokines have already been proven to be
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more efficacious than treatments with the individual cytokines such as combinations of IL12
with several different cytokines [12]. To this end, combinations of immunocytokines as well as
versions of immunocytokines wielding two cytokines have been investigated.
One such investigation looked at the benefit of using the L19 antibody conjugated to both
IL12 and TNFα (ILT). In vitro bioactivity studies showed that ILT was able to maintain the
function of both cytokines; however, in vivo studies revealed that ILT lacked any significant
tumor targeted properties. Experiments to explore the antitumor effects confirmed that ILT
showed almost no ability to reduce tumor growth, but coadministrations of L19-IL12 and L19TNFα were extremely potent for inhibiting tumor growth. In a syngeneic F9 teratocarcinoma
model, simultaneous delivery of 2 μg of each immunocytokine completely halted tumor growth
while delivery of either agent alone had almost no effect [71]. Another bifunctional
immunocytokine was more successful. This human immunocytokine, DCH, consists of two
single chain antibodies specific for epithelial cell adhesion molecule (Ep-CAM) with IL2 and
GM-CSF. In vitro assays revealed that both cytokines retain their activities and the antibodies
retain their specificities compared to non-fused versions of each [72]. For in vivo experiments, a
murine version of DCH (mDCH) was created which was similar in activity and binding affinity
to the original DCH. Treatments with mDCH in syngeneic models did result in some inhibition
of tumor growth, but it was not dependant on the tumor targeting ability of the antibody because
a non-specific immunocytokine conferred the same level of tumor inhibition. Also, treatments
with the combination of the single cytokine versions of the anti-Ep-CAM immunocytokines
resulted in similar levels of tumor inhibition [73]. These results demonstrate that combinations of
immunocytokines to exploit the synergistic effects of cytokines can create therapies with high
antitumor efficacy, but the combination of cytokines onto the same antibody has yet to show any
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further benefit. Further exploration and development of immunocytokine combinations and dualcytokine immunocytokines is needed before any significantly beneficial therapies will emerge.
Conclusions
Malignant diseases will always be a concern for humanity, and improving treatments will
always be needed. The most promising developments for treating these diseases are modulating
the immune system to identify the malignant tissue as a disease and implementing a
corresponding immune response. To accomplish this goal, cytokines are a valuable resource that
can be developed into therapies; however, the innate pleiotropic effects of cytokines makes them
a double-edged sword that can cause damage and toxicity as bad as if not worse than the
malignancy itself. So, the knowledge to properly wield this sword is paramount to utilizing
cytokines as treatments for malignancies. Fortunately, the current technology as well as
developing technological advancements is exponentially increasing to allow us to safely and
effectively use these cytokines in the near future to treat malignant diseases.
Beginning with the discovery of the EPR effect of the tumor environment, modifications
of different cytokines with PEG derivations have allowed targeting to the tumor to reach
effective concentrations in the tumor while reducing toxic concentrations in sensitive organs.
Also, PEG as also increased the ability of viruses to specifically deliver cytokine-gene payloads
to the tumor environments to achieve reduction in tumor volume while simultaneously reducing
toxicity seen with non PEGylated viruses. While this passive targeting strategy helped to
increase the functionality of cytokine therapies, more active techniques are needed to increase
the cytokine therapies to mainstream clinical applications.
Specifically targeting ligands in the tumor environment with tumor environment-specific
peptides is one such active method. These peptides have the ability to not only reach the tumor
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environment but also exhibit antitumor effects such as interrupting angiogenesis. But the true
value of these peptides lies in their ability to transfer more destructive agents such as cytokines
and viruses loaded with cytokine genes to the tumor environment. The discovery of RGD, NGR,
and their derivatives has truly helped expand the use of cytokines in cancer therapies. These
peptides can target various tumor types because they target ligands in the tumor environment and
the tumor cells. But these universal targeted peptides may not be beneficial to all patients. The
use of in vivo biopanning to discover potential ligands has been shown to identify patient specific
ligands in biopsies [74]. This strategy has the potential to make patient-specific peptide-cytokine
conjugates which will be extremely effective.
Likewise, the use of antibodies has cytokine carriers has proven to be very beneficial for
cytokine therapies. These antibodies are very specific for tumor antigens and can be
manufactured for any antigen and to be less immunogenic in patients. Also, immunocytokines
maintain their specificity for their antigens as well as the bioactivity of the cytokines. These
tumor-specific antibodies can also carry cytokine genes loaded in viral vectors to concentrate the
cytokine activities in the tumor environment while reducing toxic side effects elsewhere. There is
still much room for improvement in these therapies but promising results and preclinical
experiments continue to increase the efficacy of these treatments.
Tumor-targeted cytokine treatments are still years away from being a primary treatment
for cancer, but continued research into how to modify current treatment strategies will help bring
that goal closer every year. Also, the development of new strategies is promising improved
treatment strategies. For instance, using mesenchymal stem cells (MSC) to deliver cytokines to
the tumor environment are already appearing on the horizon. Several groups have used local
delivery of MSC loaded with cytokine genes to decrease tumor volumes, but the successful
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treatment of tumors with systemic MSC delivery has yet to be realized [17, 19]. Current and
future development of these tumor-targeted cytokine therapies is crucial for the continuing
improvement of immunomodulatory cancer treatments.
Statement of the Problem and Specific Aims
Improving cytokine gene therapy to deliver cytokines to distally located, metastatic, and
residual tumors is a promising strategy for improving tumor-targeted cytokine therapies. Results
from our lab have shown that intratumoral delivery of IL12 plasmid DNA results in tumor
eradication of 40% in a model of squamous cell carcinoma, but systemic delivery via
intramuscular administration has no effect [75]. Unfortunately, directly treating the tumors,
especially metastatic and residual, is rarely a viable option; therefore, developing a gene therapy
strategy that can be delivered systemically to produce a product that accumulates in the tumor
environment will increase the antitumor effects while decreasing the toxic side effects.
The targeting agent with the most promise for use in this strategy is a tumor-targeting
peptide. While several tumor-targeted peptides have been identified, none have been shown that
can target an in vivo produced gene product, and phage display libraries are not viable for this
strategy. So, a new screening strategy was needed, and any potential idiosyncrasies involved in
this strategy needed to be understood. So, we inserted tumor- and tissue-targeted peptides
directly before the stop codon in a reporter gene, but there were several inconsistencies when the
reporter gene activity was measured. Understanding these conflicts was critical for creating this
reporter gene screening strategy to identify the best tumor-targeted-peptide to be used in this
gene therapy approach.
Once the reporter gene method is perfected, the best tumor-targeted peptide can be
identified, and the therapeutic benefits of systemic treatments with the tumor targeted-IL12 gene
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therapy can be assessed. To achieve these goals, several experiments were performed to fulfill
the following aims:
Aim 1: Establish a method to identify peptides capable of targeting an in vivo produced
gene product to the tumor environment;
Aim 2: Identify the best tumor targeted peptide for use in this strategy;
Aim 3: Determine the therapeutic benefits of using the systemic tumor-targeted-IL12
gene therapy; and
Aim 4: Identify the receptor for the peptide.
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Chapter 2
Enhancement of Reporter Gene Detection Sensitivity by Insertion of Specific Mini-PeptideCoding Sequences*

*Reprinted with permission from Nature Publishing Group
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Introduction
Gene therapy is on the forefront of many areas of biomedical research and therapeutics.
The use of gene therapy ranges from the utilization of reporter genes for noninvasive monitoring
and gene distribution [75-77] to the application of therapeutic genes to treat several diseases such
as cancer [78-81] and blood disorders [82, 83]. Advancements in the development of both viral
and non-viral delivery systems for gene therapy result in continuous improvements in the
efficacy of gene therapy, but several barriers remain which are blocking gene therapy from
becoming widely successful.
Secreted alkaline phosphatase (SEAP) is a widely used reporter gene which is known for
its resistance to high temperature and L-homoarginine, unlike endogenous alkaline phosphatases.
SEAP is used for a variety of in vitro and in vivo assays including interferon activity [84],
efficacy of antidepressants [85], and endoplasmic reticulum stress [86, 87]. With current
strategies, the low level of gene expression of SEAP as well as other reporter genes affects the
use of reporter genes and limits their uses to in vitro and small animal models [75-77, 86, 88].
Similarly, therapeutic applications of gene therapy are hindered by having trouble acquiring
therapeutically significant levels of the gene products [89, 90]. Although improvements in gene
delivery and vector design can increase the total level of gene expression, these advancements do
not improve the sensitivity per molecule of the gene product.
To increase the level of gene expression, investigators have focused on increasing gene
delivery. For instance, several methods to increase the delivery of genes with viral vectors are
currently used. The addition of Poly(ethylene glycol) (PEG) motifs to the capsid fibers of viral
vectors, a process termed PEGylation, can increase the viral half-life by protecting the viral
particles from enzymatic degradation and increasing the circulation time. Also, PEG can protect
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the viral vectors from cell- and humoral-mediated immune responses. By improving the in vivo
viral properties, PEG can increase the level of gene delivery by the viral vectors [89]. Also,
modifying the tropism of the viruses by the addition of tissue-targeted ligands can increase the
viral load at specific sites which increases the delivery of genes at the desired location [89, 91,
92]. Similarly, plasmid delivery can be enhanced by delivery via gene gun, electroporation,
ultrasound, and many other techniques [90].
Besides gene delivery, the level and duration of gene expression may be one of the main
limiting factors for successful gene therapy. One of the most important elements that can affect
both of these factors is the promoter. The most commonly used promoter was developed from
the immediate early promoter of human cytomegalovirus (CMV) because it can increase the
level of expression in a wide range of cell types; however, the expression generated from the
CMV promoter consistently decreases beginning one to two days after transfection [93]. Other
promoters can increase the level of expression based on the tissue that is transfected. For
instance, the muscle creatine promoter can increase expression of SEAP in muscle tissues as well
as inhibiting both cell- and humoral- mediated immune responses [94]. To create more sustained
expression, synthetic promoters have been developed by combining promoters and enhancer
elements from different sources. One such promoter is the CAGG promoter which consists of the
CMV enhancer, β-actin promoter, and a chicken β-actin/rabbit β-actin globin composite intron
[82]. Composite promoters can be developed by using high throughput methods using random
assembly of promoter elements to create improved promoters [95, 96]. Other methods that are
used to increase the level and duration of gene expression include reducing the amount of
unmethylated CpG dinucleotides [80, 97], using codon optimization to remove rarely used
codons from plasmid DNA [98, 99], and decreasing the size of the vectors by using DNA
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fragments [100]. These approaches are all valuable, but current strategies have not overcome all
the hurdles to gene therapy that are caused by the low level of gene expression.
To complement these conventional approaches and increase the detection sensitivity of
each reporter molecule, here we report a novel concept—increasing the activity of the gene
product. Insertion of mini-peptide-coding sequences prior to the stop codon in SEAP-coding
DNA drastically alters the enzyme activity of the resulting SEAP enzymes. This effect occurs in
all cell lines tested as well as in two separate murine animal models. The change in detectable
levels of the enzymes is not due to a change in amount of the SEAP enzyme present but instead
is the result of a change in the activity of the SEAP enzyme.
Materials
Gene Constructs Encoding Wild-type and Peptide Conjugated Proteins. All SEAP gene
constructs were generated via direct PCR as previously described [101].
In vitro DNA Transfection via Electroporation and Reporter Gene Assays. Plasmid DNA
was transfected into cells using electroporation in the following cell lines: EC40, C2C12, 4T1,
Jurkat, and HEK293 (American Type Culture Collection, Manassas, VA). All cell lines were
maintained in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum
(DMEM) (Life Technologies, Rockville, MD). Cells were then suspended at a concentration of
1x107 cells per milliliter of Opti-mem medium (Invitrogen, Carlsbad, CA) containing 10 µg/mL
of firefly luciferase (Fluc) or Gaussia luciferase (Gluc) plasmid DNA (Valentis, Burlingame,
CA, and New England Biolabs, Inc., Ipswich, MA, respectively) as transfection efficiency
controls. 100 µL of the solution was transferred to individual electroporation cuvettes (n=3) to
which 2 µg of experimental plasmid DNA was added. Each cuvette was pulsed with one 75
msec-pulse of 150 V. The cell suspensions and 900 µL DMEM were transferred to individual
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wells of 6-well plates, and the medium was collected and replaced on specified days. If needed,
cell lysates were collected on the last day by incubating the cells with 200 µL of 1x Cell Lysis
Buffer (Promega, Madison, WI), freezing the plates at -80 °C for 20 min, thawing the plates on
ice, and collecting the lysate suspensions. All samples were stored at -80 °C until assayed.
Cell lysates and mediums were assayed for SEAP activity using the Phospha-Light SEAP
Reporter Gene Assay System (Applied Biosystems, Foster City, CA) and following the
manufacturer’s instructions. Fluc activity or Gluc acitivity was analyzed by assaying cell lysates
with the Luciferase Assay System (Promega, Madison, WI) or cell mediums with the Gaussia
Luciferase Assay System (New England Biolabs, Inc., Ipswich, MA) following the
manufacturers’ instructions. Data is presented as fold comparisons of the concentrations of
SEAP per Fluc or Gluc activity in the peptide-SEAP conjugates to the WT-SEAP.
Animal Models, In Vivo DNA Delivery via Electroporation, and Serum Collection. Six- to
eight-week old Balb/c (in-house animal breeding facility) and nude mice (Charles River
Laboratories, Inc., Wilmington, MA) were maintained under NIH guidelines approved by the
Institutional Animal Care and Use Committee of Louisiana State University. Plasmid DNA,
prepared as discussed above, was diluted in half-strength saline to 5 µg/30 µL, injected into each
rear tibialis muscle, and directly followed by electroporation (n=4) as previously described[102].
The electroporation was performed using the following parameters: two 20 msec-pulses of 35
V/mm with a 100-msec interval between pulses. Blood was collected via cheek-bleeding on days
1, 5, 10, and 15 after transfection, placed on ice for 1 h, centrifuged at 3,000 x g for 10 min to
separate the serum, and the serum was collected and stored at -80 °C until assayed as above.
Western Blot Analysis. 10 µL of serum was subjected to SDS-PAGE in a 12% polyacrylamide
gel and then transferred to a Trans-Blot Transfer Medium nitrocellulose membrane (Bio-Rad
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Laboratories, Hercules, CA). Immunoblotting of the membrane was performed with a 1:500
dilution of the primary anti-Human Placental Alkaline Phosphatase polyclonal antibody
(GeneTex, Inc., San Antonio, TX) and a 1:5000 dilution of the secondary anti-rabbit IgG
antibody conjugated to horseradish peroxidase (GE Healthcare, Piscataway, NJ). The peroxidase
signal was generated with the Western Lightning ECL (PerkinElmer, Waltham, MA) and
visualized with a Kodak Image Station 440CF using the 1D Image Analysis Software v3.6 (NEN
Life science Products, Boston, MA). All blots are representative of at least two repeat blots with
similar results.
Statistical Analyses. For all in vitro experiments, bars represent mean values of the SEAP/Fluc
or Gluc activity divided by the mean WT-SEAP values, and the labels represent the fold-change
compared to the control. For the in vivo experiments, the bars represent mean values of SEAP
activity per microliter of serum divided by the mean WT-SEAP values. One-way ANOVA
followed by Dunnett’s test was used for statistical analysis, and an asterisk (*) denotes p<0.05
comparing the SEAP-peptide mean value to the control SEAP mean value.
Results
Mini-peptide-coding Sequences Conjugated to SEAP Plasmid DNA Profoundly Affect the
Activity of the Resulting Enzyme. Phage display technology has been widely used for in vivo
biopanning to identify peptides that target tumors and other specific tissues [103, 104]. A group
of peptides that were identified as tumor-targeted were analyzed for their ability to target tumors
via insertion of mini-peptide-encoding segments directly before the stop codon on the Cterminus of SEAP plasmid DNA (Fig. 2.1); however, in experiments performed in our lab the
majority of the peptides failed to demonstrate any tumor targeting capabilities when fused with
the SEAP reporter gene via a genetic engineering method (see Chapter 3).
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Surprisingly, the different peptides caused drastic
A
changes in the detected SEAP activity 24 h after
transfection in EC40, an immortalized endothelial

B

cell line. These changes ranged from more than a 3Figure 2.1 Structure of wild-type
(WT) and the peptide modified
reporter gene plasmid DNA
constructs. (A) The SEAP control
construct. (B) Mini-peptide-SEAP
fusion gene. Mini-peptide-coding
sequences were directly inserted
before the stop codon in the same
open reading frame. CMV,
Cytomegalovirus promoter; SEAP,
secreted alkaline phosphatase; pA,
polyadenylation signal; Stop, stop
codon; Peptide, inserted peptideencoding sequences.

fold increase compared to the wild-type SEAP
(WT-SEAP) to almost undetectable activity (Fig.
2.2A). There are some changes in the SEAP
activities from cell lysates which correlates to the
previously known tumor targeted peptides which
are based on the RGD motif; however, there are no
significantly different SEAP activities in the cell
lysates (Fig. 2.2B). So, the extreme changes in

activity are not due to the peptides binding to the cell or the enzyme not being secreted from the
cell. From this broad screening, we were able to conclude that the peptides that best enhanced the
SEAP activity were CWDDWLC, TAASG, GSL, and RGD.
To further investigate whether the increased activities by inserting these peptides are cell
specific and whether insertion of these peptides results in a longer duration of increased
expression, these selected peptide-SEAP fusion gene constructs were then transfected into
murine muscle cells (C2C12), and the expression was determined for multiple days instead of
just one day after the transfection. A plasmid DNA coding for Gaussia luciferase (Gluc), which
is a secreted luciferase originating from the marine copepod Gaussia princeps [105], was
included in the transfection to correct for transfection efficiency. After transfection of these cells,
the medium was collected and replaced on days 1, 2, 3, and 4 and analyzed for SEAP and Gluc
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A

B

Figure 2.2 Differences in SEAP activity from transfection of endothelial cells with
peptide-modified SEAP reporter fusion genes. The magnitude of secreted (A) and cell
retained (B) SEAP activities from EC40 cells that were transfected with SEAP or SEAP
fusion genes. Firefly luciferase (FLuc) plasmid DNA was co-transfected for normalization of
the transfection efficiency variation. The abbreviations for each construct represent the
single-letter amino acid code except for ‘WT’ which represents the wild-type SEAP activity.
The bars represent the activity of SEAP (corrected for transfection efficiency by the activity
of luciferase) using the wild-type SEAP/Luc activity to normalize the data. Bars and
abbreviations in all subsequent figures represent the same data presentation unless otherwise
noted.
activity (Fig. 2.3A). The same as with EC40, one day after transfection the C2C12 cells
produced significantly higher peptide-SEAP activities compared to the WT-SEAP with
CWDDWLC nearing 3-fold higher activity and TAASG, GSL, and RGD at almost 2-fold higher
activities. Furthermore, the fold-increases of CWDDWLC-SEAP compared to WT-SEAP on
days 2, 3, and 4 were 2.51, 2.87, and 4.69, respectively. The other peptide-SEAP activities on
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days 2, 3, and 4 also remained higher than the WT-SEAP activities with RGD-SEAP elevating to
4-fold higher on day 4. Also, since the medium is replaced each day the increase in the activities
is not from residual SEAP remaining from the previous day but new SEAP produced in a 24 h
period. These data show that the elevated peptide-SEAP activities are not dependent on a
specific cell type and result from newly produced enzyme units.
A

B

Figure 2.3. Increase in SEAP activity by inserting the selected peptides from murine
muscle and tumor cells over time. Peptide-SEAP activity of the murine muscle cell line
C2C12 (a) and adenocarcinoma cell line 4T1 (b) after transfection with peptide-SEAP
constructs at each time point. The abbreviations are the same as described in the Figure 2.2
legend. * represents p<0.05 compared to the WT-SEAP activity.
Transfected murine tumor cells also produce increases in peptide-SEAP activities but to a
much higher degree compared to the other tested cell types. When murine adenocarcinoma cells
(4T1) were transfected in the same manner as the EC40 and C2C12 cells, all peptide-SEAP
fusion protein reached greater activity with TAASG-, GSL-, and RGD-SEAP activities ranging
from approximately 5- to 7-fold increases and CWDDWLC-SEAP having a greater than 11-fold
increase in activity compared to the WT-SEAP on day 1 (Fig. 2.3B). On days 2, 3, and 4 the
peptide-SEAP activity continued to be higher but to a lesser degree compared to day 1 with only
CWDDWLC- and TAASG-SEAP activities being significantly higher compared to the WTSEAP on day 4. These results confirm that inserting peptide-encoding-sequences to the SEAP
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encoding sequence in the same open reading frame can have drastic effects on the resulting
enzyme, and CWDDWLC is consistently the peptide that creates the highest elevation of SEAP
activity.
Modification of the CWDDWLC Sequence Significantly Alters the Activity of the Resulting
Enzyme. To further analyze whether the increase of SEAP activity by integrating the
CWDDWLC-encoding DNA is dependent on the peptide sequence, we generated a construct
containing an almost identical peptide with the insertion of one amino acid, yielding a sequence
of CWDDGWLC-SEAP. The only difference in the peptides is a Gly residue located between
the second Asp and Trp residues of the CWDDWLC peptide. We compared the activity of the
new construct CWDDGWLC- with CWDDWLC- and WT-SEAP transfected into human cell
lines.
Firstly, transfection of CWDDWLC-SEAP pDNA into human T (Jurkat), colon tumor
(HT29), and kidney tumor (HEK293) cells resulted in elevated SEAP activity compared to the
WT-SEAP similar to that seen in the murine cell lines (Fig. 2.4). For both HT29 cells and
A

B

Figure 2.4. Increase in SEAP activity by inserting the peptide in human cell lines is
amino-acid sequence specific. SEAP activity in Human T (Jurkat), colon tumor (HT29), and
kidney (HEK293) cell lines on days 1 (a), and 4 (b). The abbreviations are the same as
described in the Figure 2 legend. CWDDWLC, the selected peptide that maximizes the
SEAP activity as was shown in Figure 3. CWDDGWLC, the sequence containing one Gly
residue inserted in the CWDDWLC peptide to illustrate the sequence specificity. * represents
p<0.05 compared to the WT-SEAP activity.
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HEK293 cells, the medium was collected the same as the murine cell lines so these data show
that this phenomenon is not species specific and could translate into a clinical setting. Also, the
Jurkat cell line is not adherent so instead of collecting and replacing the medium, 50 μL of
medium was collected and assayed at every time point. The increase in CWDDWLC-SEAP
activity occurs in all human cell lines derived from different tissues (Fig. 2.4).
Secondly, the addition of the Gly residue dramatically and significantly diminished the
detectable activity of the resulting SEAP enzyme (Fig. 2.4). When the CWDDGWLC-SEAP
DNA was transfected into all three human cell lines, the activity of the enzyme was at least10fold less than the WT-SEAP activity and at least 20-fold less than the CWDDWLC-SEAP
activity. So, the increase in activity is dependent on the structure and sequence of the
CWDDWLC peptide.
Similar to the single amino acid insertion, we also tested amino acid deletion. Removal of
the Cys residues that flank the peptide completely abolished the effect of the peptide on the
SEAP activity (Fig. 2.5). In both C2C12 and HT29 cell lines, transfection with the CWDDWLCB

A

Figure 2.5. Removal of the flanking Cys residues reduces the SEAP activity to the WTSEAP level. SEAP activity in both human (HT29) and murine (C2C12) cell lines on days 1 (A)
and 4 (B). CWDDWLC-SEAP, the reporter gene modified with the selected peptide coding
sequence that maximizes SEAP activity. WDDWL-SEAP, the same selected peptide without the
flanking Cys residues. * represents p<0.05 compared to the WT-SEAP activity.
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SEAP plasmid DNA repeatedly showed increased SEAP activity compared to the WT-SEAP
transfected cells; however, Cys-less WDDWL-SEAP encoding plasmid DNA transfected cells
produced levels of SEAP activity that were not significantly different than transfection with WTSEAP encoding DNA (Fig. 2.5).
The Same Trends in Activity are Seen with In Vivo Transfection but with No Difference in
the Level of SEAP Protein. After demonstrating that the increased activity seen by conjugating
CWDDWLC to SEAP plasmid DNA occurs in all tested cell lines, the next step was to see if this
effect also occurs in vivo, which determines the ultimate application value for reporting
purposes. To determine this effect in vivo, mice were injected with 5 µg of peptide-SEAP
plasmid DNA or WT-SEAP followed by electroporation in each rear tibialis muscle.
The same as seen in vitro, the CWWDWLC-SEAP activity was near 6-fold higher than that of
the WT-SEAP activity on days 1 and 5 (Fig. 2.6). Interestingly, the WDDWL-SEAP activity did
A

B

Figure 2.6. Changes in peptide-SEAP activity from in vivo transfections. Mice were
injected with 5 µg of plasmid DNA into each rear tibialis muscle followed by
electroporation, and serum was collected and analyzed for SEAP activity on days 1 (A) and
5 (B). * represents p<0.05 compared to the WT-SEAP activity.
appear to be increased on day 1, but this increase was not statistically significant, and by day 5 it
was relatively the same as the WT-SEAP activity. Likewise, the CWDDGWLC-SEAP activity,
while still significantly lower than the WT-SEAP, was only about 4-fold less than the WT-SEAP
as compared to 10-fold less as seen in the in vitro data; however, by day 5 the CWDDGWLC-
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SEAP activity was undetectable in the serum. A similar experiment performed using nude mice
treated with either CWDDWLC-SEAP or WT-SEAP plasmid DNA revealed similar results with
differences in SEAP activity in the serum (data not shown).
To determine if the changes in activity result from differences in the concentration of the
SEAP protein, serum samples from each group on days 1 and 5 were analyzed via western blot
using an antibody that is specific for the SEAP protein and does not bind endogenous mouse
A

B

C

D

Day 1
Day 5

alkaline phosphatases. Astonishingly, the western blot
revealed that there is no correlation between the

Figure 2.7. Serum SEAP activity
levels do not correspond to changes
in the amount of SEAP protein
present in the serum. The same serum
samples assayed in Figure 6 were
analyzed via western blot, and there
were no differences in the amount of
the SEAP protein present for WTSEAP (A), CWDDWLC-SEAP (B),
CWDDGWLC-SEAP (C), and
WDDWL-SEAP (D).

changes in activity from the peptide-SEAP constructs
and actual levels of the SEAP protein on any of the
days tested (Fig. 2.7). Even on day 5 when there was
an almost undetectable level of CWDDGWLC-SEAP
activity, there is no difference among the amounts of
SEAP protein present in any of the groups.

Discussion
For the first time we show the dramatic effects that small peptides can have on the
activity of SEAP due to integration of mini-coding-peptide sequences into the SEAP coding
sequence in the same open reading frame. These peptides were believed to have tumor- and
tissue-targeting abilities [103], but the majority failed to show any targeting abilities in
experiments performed in our lab (unpublished data). This result does not mean that these
peptides do not have such tumor-targeted property, but instead it suggests that the peptides have
to be meticulously used for the purpose of tumor targeting. Genetically engineering these
peptides with this reporter gene seems to not be the best approach to exhibit the tumor-targeted
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property of these peptides, but when some of these peptides are fused with other viral vector
genes, tumor-tropism was improved [92, 106, 107].
Interestingly, we found that the peptides had extreme effects on the activity of SEAP
reporter gene to which they were fused in the same open reading frame (Figs. 2.2-2.5). Several
methods are currently employed to increase the levels of gene products from the in vitro and in
vivo delivery of DNA. Increasing the level of gene delivery is one area of focus for increasing
the products of gene therapy. To accomplish this feat, several different modalities are used
including the modification of viral vectors to elongate circulation times, reduce immunogenicity,
and increase the accumulation of viral particles at target areas [89, 91, 92]. Also, the level of
gene transfection with plasmid DNA can be increased by using several different techniques such
as gene-gun, electroporation, ultrasound, and several others [90]. Likewise, increasing the level
and duration of transgene expression can be accomplished by other specific methods: intuitive
promoter selection [82, 93-96], decreased unmethylated CpG levels [80, 97], optimized codon
use [98, 99], and decreased size of transfected DNA [100]. Another manner is to increase the
activity per molecule of gene products which has been accomplished via DNA shuffling for
green fluorescent protein [108]. DNA shuffling and the new method reported here for increasing
the activity of gene products has the potential to work in concert with these other widely used
methods to further increase the efficacy of gene therapy. This concept should be tested in the
future since it may improve the sensitivity of this reporter gene.
The increase in activity by insertion of the discovered peptide occurs in a gene-specific
manner because the same peptide that enhances SEAP activity only slightly increases the
expression of MHCI, a hallmark indicator of IFNa biological activity [109], by CWDDWLCIFNα compared to wild-type IFNa (data not shown). The increase was neither statistically
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significant nor therapeutically relevant. So, the large increase in activity seen in SEAP by the
CWDDWLC peptide is not universal; however, other peptides may increase the biological
activity of different therapeutic proteins. Screening several different peptides for individual
proteins is necessary to discover the most effective peptide-protein combinations, which is the
central concept for this MS. This concept is also different from the DNA shuffling technique in
that the recombinant protein from DNA shuffling is generated through using variants of the same
gene from the same and/or different species [110] while our concept is to insert a peptide at the
N or C terminal to increase the protein function.
One possible explanation for these dramatic differences would be that the peptides are
interacting with cell surface ligands. Several of these peptides were thought to be targeted to the
upregulation of certain proteins on the surface of cells during neovascularization due to tumor
development [78, 79, 111-113]. Another explanation could be that the peptides somehow
affected the secretion signal in the SEAP protein so the SEAP remained in the cell. However,
these differences were not a result of peptide interactions with cell surface motifs or a loss of a
secretion signal because the cell lysates did not show any significant differences in SEAP
activity between the WT-SEAP and any peptide-SEAP groups (Fig. 2.2B). Also, this change in
activity was not dependent on the type of cell because the same differences were seen when
murine muscle cells (C2C12) and adenocarcinoma cells (4T1) were transfected with the same
SEAP constructs (Fig. 2.3A,B, respectively). Likewise, this effect is also not restricted to murine
cells because the same effects are evident in human immune (Jurkat), colon tumor (HT29), and
kidney tumor (HEK293) cell lines (Fig. 2.4). The varying activity levels of SEAP seen in the
different cell types can be attributed to the cell-dependent activity of the CMV promoter. While
CMV is a broadly used promoter for different cell lines and animal models, it is not always the
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best choice for all cell types [82, 93, 95, 96], and modulation of the promoter based on the tissue
to be transfected could lead to higher expression levels which will further increase the level of
activity of the CWDDWLC-SEAP. So, the effects that the peptides have on the SEAP activity
levels are not restricted to a certain cell type nor are they specific to a certain species. These facts
are very important for the translation of the use of these highly sensitive reporter genes into other
models such as large animals.
The sequence of the CWDDWLC peptide is very important for the increased activity
effect to occur. Modification of the sequence by introducing a Gly residue between the second
Asp and Trp residues rendered the resulting enzyme almost inactive (Fig. 2.4). Further
modification of the sequence by removing the flanking Cys residues also had serious
consequences to the activity of the resulting SEAP enzyme. Interestingly, the loss of the Cys
residues reduced the activity of the SEAP to almost identical the activity of the WT-SEAP
enzyme (Fig. 2.5). Interestingly, peptides with flanking Cys residues typically form loop
secondary structures resulting from a disulfide bond between the two residues [114]. So, one
possible explanation for the loss of the increase in activity could be due to the loss of the loop
structure.
Another important aspect of this phenomenon is that it also occurs in vivo. As seen by
measuring the SEAP activity in the serum of mice treated with the WT-SEAP, CWDDWLCSEAP, and both modified peptide-SEAP constructs, the increase in CWDDWLC-SEAP activity
as compared to the WT-SEAP continues for at least 5 days in both Balb/c (Fig. 2.6) and nude
mice. By days 10 and 15, the SEAP activity in all groups is reduced to insignificant levels (data
not shown), which is most likely the result of an immune response against SEAP which is an
enzyme of human origin. Amazingly the level of SEAP protein present in the serum of these
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mice is the same regardless of the activity of the different SEAP enzymes (Fig. 2.7). So, the
differences in the detectable levels of the SEAP enzymes are due to changes in the activity of the
enzymes and not differences in the amounts of SEAP produced.
One of the main restraints which continues to hinder gene therapy is the level of gene
expression, and several methods attempt to break these chains that bind gene therapy. There
continues to be progress in this field, and the simultaneous use of multiple methods to increase
the efficacy of gene therapy is important for gene therapy to become a major element in
biomedical research and therapeutics. The use of peptides to increase the activity of proteins to
which they are conjugated has the potential to be another method to synergistically increase the
efficacy of gene therapy.
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Chapter 3
Discovery of a Linear Peptide for Improving Tumor Targeting of Gene Products and
Treatment of Distal Tumors by IL12 Gene Therapy
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Introduction
Interleukin 12 (IL12), discovered by Giorgio Trinchieri in 1989 [115], bridges the innate
and adaptive immune responses by inducing IFNγ production primarily from natural killer and T
cells. Cancer therapy with IL-12 exploits its natural immune functions to polarize T cells to the
Th1 phenotype, boost effector T cells, downregulate angiogenesis, remodel the extracellular
matrix, and alter the levels of immune suppressive cytokines [116]. Due to these activities, IL12
is one of the most promising cytokines for immunomodulatory cancer therapy.
The initial clinical trials with IL12 resulted in grave toxicities including deaths, which
severely downgraded the reputation and potential application of this effective cytokine. In
reality, most anticancer drugs or biological modalities are associated with systemic toxicity. It is
imperative to solve this problem for effectively and safely treating the extremely high numbers
of cancer patients [116].
A popular strategy for sequestering the effects of cytokine therapies in the tumor
environment is targeting cellular markers that are upregulated exclusively in the tumor cells or
the tumor microenvironment. Indeed, conjugating IL12 to tumor-specific antibodies, such as L19
[117] and HER2 [118], and tumor vasculature-specific peptides, such as RGD [119] and
CNGRC [120], improves the efficacy of treatments; however, frequent administrations of
recombinant cytokines are needed which increase the immunogenicity, toxicity, and cost. A gene
therapy approach would reduce these limitations.
Intratumoral IL12 gene therapy is able to eradicate 40% of tumors in an SCCVII model
while systemic delivery via intramuscular administration fails to eradicate any tumors [121];
however, direct injection into tumor sites is rarely noninvasively or post-surgically available.
Several methods have been developed to target the IL12 effect to the tumor after systemic
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delivery. For example, modifying viral vectors with tissue specific gene promoters such as the
CALC-I promoter [122], capsid-expressed tumor-specific peptides [123], and polyethylene
glycol or other nanoparticles [124, 125] increases tumor specific expression and decreases
systemic expression; however, the fenestrated vasculature of the tumor environment allows for
the gene products to leak out of the tumor environment leading to systemic toxicities [126]. So, a
gene product that can interact with and remain in the tumor environment will increase the level
of therapeutic efficacy and decrease systemic toxicity.
To this end, we used an in vivo reporter gene mediated screening strategy [127] to
identify a new tumor targeting peptide, VNTANST [128]. A DNA fragment encoding
VNTANST was inserted directly before the stop codon of the IL-12 encoding sequence in
plasmid DNA. Transfection of this plasmid DNA via intramuscular (i.m.) electroporation (EP)
into muscle tissue distal from the tumor site inhibited tumor growth and extended survival in
multiple tumor models and two mouse strains and reduced lung metastasis in a spontaneous
metastatic model. Due to this broad targeting nature and to simplify the description, the peptide
VNTANST was renamed the Comprehensive Carcinoma Homing Peptide (CHP). Also, we
identified the receptor for CHP as vimentin, which is upregulated in several tumor types.
Vimentin expression in tumors is associated with the epithelial to mesenchymal transition (EMT)
and increased malignancy and metastasis in tumors [129-133]. Lastly, this gene product-targeted
approach minimized the risk of IL12-induced toxicity.
Materials
Plasmid DNA Preparation. All SEAP gene constructs were generated via direct PCR as
previously described [127]. The wild type IL12 gene construct (wtIL12) was obtained from
Valentis, Inc. (San Francisco, CA) [134], and gene sequences encoding the peptide sequences
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were inserted directly prior to the stop codon of the IL12 p40 subunit encoding region using the
primer sequences listed in Table 3.1. The IL12 plasmid includes both the p35 and p40 subunits.
The control plasmid DNA (Control) consisted of a deletion of the IL12 gene from the IL12
construct. All plasmid DNAs were manufactured with the Qiagen EndoFree plasmid preparation
kit (Alameda, CA).
Table 3.1 Primers for PCR.
Peptide

SEAP Constructs
Forward Primer 5'-3'

Reverse Primer 5'-3'

CGFELETC

CCAGGATCCTAAAAGGGCAG

TTATCACTCGAGGCAAGTCTCTAGCTCGAATCCACATG
TCTGCTCGAAGCGGCC

NGYEIEWYSWVTHGM
Y

CCAGGATCCTAAAAGGGCAG

TTATCAGTACATACCGTGAGTAACCCAGGAGTACCAC
TCGATCTCGTAACCGTTTGTCTGCTCGAAGCGGCCGG

TAASGVRSMH

CCAGGATCCTAAAAGGGCAG

ATWLPPA

CCAGGATCCTAAAAGGGCAG

CNGRC

CCAGGATCCTAAAAGGGCAG

HTMYYHHYQHHL

CCAGGATCCTAAAAGGGCAG

GSL

CCAGGATCCTAAAAGGGCAG

NSSRGLG

CCAGGATCCTAAAAGGGCAG

RGD4C

CCAGGATCCTAAAAGGGCAG

TTATCAATGCATACTACGGACACCACTAGCAGCAGTT
GTCTGCTCGAAGCGGCCGG
TTA TCAAGCTGGA GGGAGCCACG TAGCTGTCTG
CTCGAAGCGG CCGG
TTATCAACAACGACCGTTACATGTCTGCTCGAAGCGG
CCGG
TTATCAAAGGTGATGCTGATAGTGATGGTAATACATA
GTGTGTGTCTGCTCGAAGCGGCCGG
TCGTCTAGATTATCACAGACTTCCACCCGGGTGCGCG
GCGTCG
TTATCAACCGAGATCCCTACTGCTGTTTGTCTGCTCGA
AGCGGCC
TTATCAGCAGAAACAATCACCGCGGCAATCACA

IL12 Constructs
Peptide
VNTANST
CDGRC

Forward Primer 5'-3'

Reverse Primer 5'-3'

GTCGACCCCGCCCAAGAAC
TTGCAG
GTTCGAATCTGCGATGGAA
GATGCCAGCGCAAGAAAGA
AAAG

ACTAGTTTATCAAAGCTTTGTCGAGTTAGCCGTGTTGAC
GGATCGGACCCTGCAGGGA
GAACAAAAGCTGGTACCGG

Cell lines, In Vitro Gene Transfer, and IFNγ Induction. CT26, SCCVII, 4T1, EMT6, and
B16F10 cell lines were obtained from American Type Culture Collection (ATCC, Manassas,
VA), the AT84 cell line was a generous gift from Dr. Edward Shillitoe (State University of New
York Upstate Medical School), and MCF7 cells were provided by Dr. Bolin Liu (University of
Colorado Denver School of Medicine). All cell lines were maintained in Dulbecco’s modified
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Eagle’s medium containing 10% fetal bovine serum (DMEM) (Life Technologies, Carlsbad, CA)
at 37 °C and 5% CO2.
For in vitro transfections, 4T1 cells were suspended at a concentration of 1x107 cells/mL
Opti-mem medium (Life Technologies), and 100 µL of this suspension were transferred to
individual electroporation cuvettes and 2 µg of Control, wtIL12, CDGRC-IL12, or CHP-IL12
plasmid DNA was added (n=3). Each cuvette was pulsed with one 75-ms pulse of 150 V, and the
suspensions were transferred to individual wells of a 6-well plate containing 900 µL DMEM.
The next day, 900 µL of medium was collected, placed on ice, and analyzed for the presence of
IL12p70 using an IL12p70 ELISA (eBiosciences, San Diego, CA) as per the manufacturer’s
instructions. The spleen from a naïve Balb/c mouse was placed in serum-free RPMI-1640
containing Pen/Strep/Glu (RPMI), splenocytes were filtered through a 70 µm cell strainer, and
suspended in 10 mL RPMI. After the cell suspension was centrifuged for 10 min at 1,000 rpm,
the supernatant was removed, cells resuspended in 10 mL RBC lysis solution, centrifuged again,
and then resuspended in RPMI at a concentration of 2x106 cells per 100 µL. 2x106 cells were
placed into wells of a 6-well plate. Condition medium from the plasmid DNA-transfected cells
containing 150 pg/mL IL12 was transferred to these wells and the volume was adjusted to 1 mL
with DMEM. The next day, the mediums were collected and assayed for the presence of IFNγ
using an IFNγ ELISA (eBiosciences) as per the manufacturer’s instructions.
Animal Models, Tumor Inoculations, In Vivo Gene Transfer, Protein Extraction, and
Therapeutic Analyses. All animals used in this study were maintained under and animal
protocols were performed following National Institutes of Health guidelines, approved by the
Institutional Animal Care and Use Committee (IACUC) of Louisiana State University. Balb/c
mice were obtained from the in-house breeding colony, and C3H, Nude, and wtIL12-/- mice were
obtained from Charles River Laboratories (Wilmington, MA). All mice were six to eight weeks
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old upon initiation of experiments. Tumor models were initiated via subcutaneous inoculations
of 30 µL cell suspensions containing 1x105 4T1 cells or 2x105 cells for all other cell lines in 1x
PBS. Orthotopic EMT6 tumors were initiated by inoculating 1x105 cells in the mammary fatpads
of female Balb/c mice.
For in vivo i.m gene transfections, plasmid DNA was diluted in 0.45% NaCl to a
concentration of 5 µg/30 µL was injected into each rear tibialis muscle, and the muscles were
immediately subjected to EP as previously described [135]. When 4T1 tumors were 3 to 4 mm in
diameter or all other tumor models were 4.0 to 4.5 mm in diameter, the first treatment was
performed, and a second identical treatment was performed 10 days later. Tumor volumes were
determined as previously described [127]. To determine the distribution of the fusion gene
products peptide-SEAP and peptide-IL12, the treatments were performed when tumors reached
6-7 mm in diameter; 72 h after treatment, mice were sacrificed via CO2 asphyxiation, and then
tissues were collected, wrapped in foil, and flash-frozen in liquid nitrogen (LN). To extract
proteins, the frozen tissues were smashed with a hammer, placed in 1x lysis buffer (Promega,
Madison, WI), beaten for 1 minute with a mini-beadbeater 8 (Biospec, Bartlesville, OK), and
spun at 16,000 x g for 5 min. The supernatant was transferred to a new tube. Serum was
collected by extracting blood from the left ventricle, transferring it to Serum Separator Tubes
(BD, Franklin Lakes, NJ), and spinning at 5,000 x g for 5 min. The serum was then transferred to
a new 1.5 mL tube.
India ink inflation was performed to determine the level of lung metastasis. After CO2
asphyxiation, the thoracic cavity was opened, the trachea exposed, and the trachea clipped with a
hemostat. 1.5 mL 15% India ink was injected into the lung which was then transferred into 20
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mL Fekete’s solution and incubated overnight. The next day, white metastatic nodules were
counted using a dissecting microscope.
For FACS analyses, tumor infiltrating cells were isolated by extracting the tumors,
cutting them into pieces, and resuspending the mixture in sterile PBS (without Ca2+ and Mg2+)
containing a mixture of collagenase IV, hyaluronidase V (Sigma-Aldrich, St. Louis, MO), and
DNase II (Fisher, Pittsburgh, PA). The tissue suspension was placed in a shaker at 37 ºC for 1-2
hours, and then poured through a 70 µm cell strainer, followed by washing twice in PBS with
Ca2+ and Mg2+. The isolated cells were stained with the FITC conjugated anti-CD11c (AbD
Serotec, Raleigh, NC) and goat anti-mouse CD80 (R&D, Minneapolis, MN) for 30 min at 4˚C ,
washed with PBS, and then stained with PE conjugated anti-goat IgG (Cedarlane Laboratories,
Burlington, NC) . The expression of the proteins was analyzed on FACS Calibur (BD
Biosciences, San Jose, CA) and analyzed with FCS Express 3 (De Novo Software, Los Angeles,
CA). Splenocytes were also isolated from Balb/c mice bearing orthotopic EMT6 tumors, and a
CTL assay was performed as described previously [127]. Serum was collected from 4T1-tumor
bearing mice 3 days after treatments with Control, wtIL12, and CHP-IL12 plasmid DNA as
described above. The serum was analyzed for the presence of IFNγ as described above.
Peptide-biotin Distribution, Vimentin Depletion, and Tissue Staining. CHP-biotin was
synthesized by United Biochemical Research, Inc. (Seattle, WA) at >95% purity, resuspended in
H2O with 5% glycerol, and stored at -80 °C. The peptide sequence is NH2-VNTANSTGG-biotin.
Control-biotin was created by conjugating a non-specific peptide (CTSTSPLPPPSHSTSKKG,
Alpha Diagnostics, San Antonio, TX) to EZ-Link Amine-PEG2-Biotin via 1-Ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC) cross-linking (Pierce, Rockford, IL) following the
manufacturer’s instructions. The peptide-biotin conjugates (10 µg/100 µL normal saline) were
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injected into the tail vein of C3H mice bearing SCCVII tumors with 6-7 mm diameters. For
vimentin depletion studies, goat polyclonal anti-vimentin (Millipore, Billerica, MA) was purified
via protein-G antibody purification (Pierce), and 150 µg was added to the peptide-biotin
conjugate solutions for administration. One hour after i.v. administration, mice were perfused via
injection of 10 mL 1x PBS into the left ventricle after cutting the right atrium. The tissues were
immediately removed, wrapped in foil, and flash frozen in LN. Four- to five-micron sections
were placed on poly-L-lysine coated slides.
The sections were fixed in ice-cold acetone, non-specific interactions were blocked with
1% BSA in PBS, and endogenous peroxidase activity was suppressed with Stable peroxidase
suppressor (Pierce). Since the peptides already contained biotin, the peptides were incubated
with the avidin-HRP reagent Vectastain ABC (Vector Biolabs, Philadelphia, PA) for 45 min,
washed in PBS, and then incubated with 1x Metal Enhanced DAB (Pierce). The sections were
then counter-stained with Meyer’s hematoxylin (blue) for 2 min or eosin (pink) for 20 s.
Isolation of Cell Surface Proteins, Identification of CHP Receptor, and Western Blot. Cell
surface proteins were isolated from SCCVII cells using the Cell Surface Protein Isolation Kit
(Pierce) and following the manufacturer’s instructions. A streptavidin agarose column (Peirce)
was loaded with CHP-biotin (3 mg/mL in PBS for 10 min), and the cell surface protein
suspension was incubated on the column overnight at RT. Next, five fractions were eluted with 8
M Guanidine-HCl, pH 1.5, and then 1 M Na2HPO4 was added to the fractions at a 1:10 ratio.
From these fractions, volumes containing 40 µg of protein were mixed with 2x SDS loading
buffer and added to wells of a 12% polyacrylamide gel and an electric field was applied. The gel
was then incubated with Coomassie Brilliant Blue R250 followed by destaining solution (10%
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Acetic Acid and 20% MeOH). Images were captured with a VersaDoc Model 1000 and Quantity
One Version 4.4.1 software (BioRad, Hercules, CA).
To identify the protein from fraction two, the protein in the gel was extracted using the
Trypsin Profile IGD Kit (Sigma) with the ProteoPrep Reduction and Alkylation Kit (Sigma)
following the manufacturer’s instructions. Liquid chromatography electrospray tandem mass
spectrometry (LC MS/MS) was used to analyze the peptide mixture extracted from gel spots.
Tryptic digests of gel spots (~6 μl) were diluted with 0.1% formic acid (10 μl) and 10 μl injected
by microplate autosampler (Famos, Dionex Corporation, Sunnyvale, CA) onto a 0.3 x 1 mm
trapping column (PepMap C18, Dionex Corporation) using a nano LC system equipped with
Switchos and Ultimate 2000 pumps (Dionex Corporation), at a flow rate of 10 μl/min. The
switchos valve was set on loading position prior to sample loading. After sample loading
trapping column was washed with 0.1% formic acid at flow rate of 5ul/min for additional 5 min
and then switchos valve was switched to inject position. Peptides were then eluted at 200 nl/min
and chromatographed on a 75 μm x 15 cm Biobasic C18 column (Vydac HPLC Columns, Grace
Davison, IL), with a gradient of 5-40% acetonitrile over 60 min followed by 80% acetonitrile for
5 min. The eluent was directed into a quadrupole time-of-flight mass spectrometer (Q-Star,
Applied Biosystems MDS Sciex) and ionized immediately using electrospray source (Nano
spray II, Applied Biosystems MDS Sciex) at high voltage of 2.5 kv with nebulizer gas at level 2.
The mass spectrometer was operated in IDA (information dependent acquisition) mode with the
three most intense ions in each survey scan subjected to MS/MS analysis using collision energies
ranging from 20 eV to 50 eV. MS/MS data obtained from Q-Star was processed for database
search using Mascot search engine (Matrix science, UK). A Mascot search was performed using
the following parameters: Type of search, MS/MS ion search; Database, nrNCBI; Taxonomy,
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all; Enzyme, trypsin; Fixed modification, carbamidomethyl (C); Mass values, monoisotopic;
Protein mass, unrestricted; Peptide mass tolerance, + 0.2 Da; Fragment mass tolerance, + 0.2 Da;
and Maximum miss cleavage, 1. The results and matched peptides from the Mascot search are
listed in Appendix A.
A cell-free assay was developed to confirm that vimentin interacts with CHP. Wells of a
microtiter plate were coated with 50 µL of 100 mM NaHCO3 (coating buffer) or 5 µg/mL of
either vimentin-GST or GST (ProSpec) in coating buffer and incubated at 4°C overnight. After 2
washes with PBS, non-specific binding was blocked by incubating the wells with 100 µL 1x
BSA for 2 h at room temperature (RT). After another wash (twice), 100 µL of PBS containing 10
ng CHP-biotin was added to each well (n=6 for each coat), incubated for 2 h at RT, and then
washed 4 times with PBS. Avidin-HRP (100 µL, eBiosciences) was added to each well,
incubated for 30 min, and the wells were washed 7 times with PBS. Lastly, 100 µL TMB
substrate (eBiosciences) was added to each well for 15 min followed by 50 µL Stop solution
(eBiosciences), and the absorbance at 450 nm was read using a SpectraCount and PlateReader
Version 3.0 software (PerkinElmer, Waltham, MA).
To prepare cells for western blot analysis of cellular expression of vimentin, when
SCCVII, CT26, 4T1, and B16F10 cells were 95% confluent in individual wells of 6-well plates,
the cells were directly lysed with 60 µL Laemmli sample buffer. For preparation of ex vivo
samples, tissues and tumors were processed as described previously. Volumes of the tissue
lysates containing 40 µg of protein were mixed with 2x SDS loading buffer. Twenty microliter
volumes of the cell lysates or tissue lysates were added to a 12% polyacrylamide gel and
subjected to SDS-PAGE and then transferred to a TransBlot Transfer Medium nitrocellulose
membrane (Bio-Rad Laboratories). Immunoblotting of the membrane was performed with a
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1:100 dilution of polyclonal Goat anti- vimentin (Millipore) and a 1:5,000 dilution of the
secondary horseradish peroxidase conjugated rabbit anti-goat IgG. The peroxidase signal was
generated with the Western Lightning ECL (PerkinElmer) and visualized with a Kodak Image
Station 440CF using the 1D Image Analysis Software v3.6 (PerkinElmer).
Analysis of Toxicity Induced by Gene Therapy Treatments. SCCVII tumors were induced in
C3H mice as described above, and allowed to grow to a volume of 300 mm3. Groups of four
mice for each treatment at each time point were treated with either wild-type IL-12 or CHP-IL12 as described above at a dose of 1 g, 2 µg, and 10 µg plasmid DNA; a fourth set of mice
received 3 treatments of 2 µg. Mice were sacrificed on days 1, 3, and 30 after the second
treatment, blood was collected in serum separator tubes, and livers were fixed in 10% neutralbuffered formalin.
Serum chemistry profiles were analyzed by a private GLP-certified diagnostic laboratory
(Antech Diagnostics, Memphis, Tennessee). Formalin-fixed tissue was cut-in, embedded in
paraffin, and sectioned into 5 μm sections. Sections were mounted on glass slides and stained
with hematoxylin and eosin prior to microscopic examination by a pathologist. A liver toxicity
scoring system based on the number of characteristic liver lesions (foci of hepatocellular necrosis
with Kupffer cell hyperplasia) per 200x field. Sections were scored blindly and recorded for
analysis.
Statistical Analyses. All statistical analyses were performed with GraphPad Prism version 5.00
for Windows, (GraphPad Software, San Diego, CA). One-way ANOVA with Bonferroni’s posthoc test was used to analyze the following data: ratios of Tissue/Serum (T/S) SEAP levels,
production of fusion gene products from in vitro transfected 4T1 cells, inhibition of metastasis,
IFNγ serum levels, and CHP/vimentin interaction. Tumor versus normal tissue distributions of
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exogenous IL12 or CHP-IL12 gene products in IL12-/- mice and CTL data were analyzed via
one-tailed unpaired T tests. All tumor growth experiments were analyzed via two-way ANOVA
plus Bonferroni’s post-hoc test. Mantel-Cox tests were used to analyze differences in survival of
mice. Liver toxicity was first analyzed using blind pathological scores of the liver tissues, but no
differences were seen among time points, so the data was pooled to create a larger sample size
and then analyzed with one-sided Fisher’s exact tests comparing the number of mice having
lesions from CHP-IL12 and wtIL12 fusion plasmid DNA treated mice.
Results
CHP Increases Accumulation of the Fusion Reporter Gene Product and Biotin-CHP
Conjugate into Tumors. Several fusion gene constructs were cloned by inserting peptide
encoding DNAsequences directly prior to the stop codon in a secreted alkaline phosphatase
(SEAP) reporter plasmid DNA (Fig. 3.1A) [127]. These peptide-SEAP fusion gene constructs
were delivered via i.m. EP of the anterior tibialis muscles in mice bearing tumors located 1 cm
craniodorsal of the tail. After 72 h, tumors and serum were collected and analyzed for SEAP
distribution. It has been shown that inserting peptides into the SEAP plasmid can alter SEAP
activity but not protein production [135]. To compensate for the altered SEAP activity, we used
the ratio of the SEAP activity between tumors and serum (T/S SEAP).
CHP, a linear peptide, repeatedly increased the T/S SEAP levels in several tumor models
compared to wtSEAP. In Balb/c mice bearing colon carcinomas (CT26), CHP showed the
greatest increase in T/S SEAP (orange; Fig. 3.1B). To identify the peptides with potential for
targeting multiple tumor models, some of these peptides were also tested in other models. In two
squamous cell carcinoma models (SCCVII and AT84) in C3H mice, 5- and 7-fold increases in
T/S SEAP were seen, respectively, for CHP-SEAP (red and blue, respectively; Fig. 3.1B). In a
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breast adenocarcinoma model (4T1) in Balb/c mice, T/S SEAP was increased 15-fold for CHPSEAP compared to wtSEAP (green; Fig. 3.1B). Importantly, the gene product targeting property
of CHP was also confirmed in a xenogeneic human breast cancer model (MCF7) with a 4-fold

Figure 3.1. Accumulation of peptide-SEAP reporter gene products and CHP-biotin in
tumors. (A) The peptide-SEAP constructs with insertion of the peptide-coding sequence
directly before the stop codon (blue arrow). (B) T/S SEAP levels 72 h after intramuscular EP
of peptide-SEAP plasmid DNA in syngeneic CT26 (orange, n=3), SCCVII (red, n=4), AT84
(blue, n=4), and 4T1 (green, n=4) tumor-bearing mice as well as xenogeneic MCF7 tumorbearing mice (purple, n=4). Columns represent the ratio of the control-normalized
SEAP/protein (pg/mg) in tumor to SEAP (pg/mL) in the serum and error bars represent s.e.m.
(* represent p<0.05 compared to wtSEAP). (C and D) DAB staining of tumor tissues from
CHP-biotin and Control-peptide-biotin treated mice counterstained with either hematoxylin
(blue) or eosin (pink). The bottom images are larger versions of the areas within the white
squares. Scale bars represent 100 µm in the top panels and 200 µm in the bottom panels. EP,
electroporation; CMV, Cytolmegalovirus promoter; IVS, intron; SEAP, SEAP-coding
sequence; STOP. Stop codon; pA, bovine growth hormone polyadenylation signal.
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increase in T/S SEAP (purple; Fig. 3.1B), which suggests this peptide has potential application
for human tumors.
In addition to the quantitative T/S SEAP data above, we were interested in visualizing the
CHP distribution in the tumors and throughout the body. To easily detect the localization of this
targeted peptide, synthetic CHP-biotin conjugate or a control-peptide-biotin conjugate (Controlbiotin) was injected into the tail vein of SCCVII tumor bearing C3H mice. CHP preferentially
accumulated deep into the tumor environment, and, as seen in slides counterstained with either
hematoxylin (Fig. 3.1C, top and bottom left) or eosin (Fig. 3.1C, top and bottom right), the
CHP-biotin localized in the tumor tissue (19.6 ± 1.3 positive per field, n=5 fields). In contrast,
Control-biotin was not able to penetrate deep into the tumor tissues (1.8 ± 0.37 positive per field,
n=5 fields, p<0.0001 compared to CHP-biotin) (Fig. 3.1D). Negligible levels of biotin
accumulated in the hearts, lungs, livers, and kidneys of mice treated with either CHP- or Controlbiotin; however, similar levels of CHP-biotin and Control-biotin were detected in the spleens
(Appendix B), most likely due to non-specific uptake by the efficient mononuclear phagocytes
bounding splenic red pulp sinuses.
CHP-IL12 Gene Product Maintains Targeting and Biological Functions. Peptide-IL12
fusion gene constructs were generated by inserting the peptide coding sequences directly before
the stop codon of the p40 subunit in an IL12 plasmid DNA (Fig. 3.2A) [135]. CHP-IL12,
CDGRC-IL12, wtIL12, or empty vector plasmid DNA were transfected into 4T1 cells. After 24
h, equivalent levels, ~175 pg/µL, of the IL12p70 heterodimer were detected in the medium of all
three IL12 gene plasmid DNA transfected cells, and negligible IL12p70 was detected in the
control wells (Fig. 3.2B). Transferring the IL12 containing medium to splenocytes induced
similar levels of IFNγ, a hallmark of IL12 function (Fig. 3.2C) indicating that these fusion IL12
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proteins possess the same biological function as wtIL12.The distribution of CHP-IL12 in the
tumor, kidney, liver, and serum was determined via IL12p70 ELISA 72 hours after treating
CT26 tumor-bearing IL12 knockout Balb/c (IL12-/-) mice with the CHP-IL12 and wtIL12
plasmid DNA. The CHP-IL12 protein localized in the tumor environment as seen by the 4-fold
increase in T/S IL12 ratio compared to wtIL12 (orange, Fig. 3.2D). Likewise, CHP-IL12
increased the Tumor/Kidney and Tumor/Liver IL12 ratios compared to wtIL12 (green and blue,
respectively; Fig. 3.2D). So, a single copy of the CHP peptide is capable of targeting each IL12
molecule to the tumor microenvironment.

Figure 3.2. Biological activity and targeting ability of peptide-IL12 fusion
gene products. (A) The peptide-IL12 constructs with insertion of the peptidecoding sequence directly before the stop codon in the p40 coding region (blue
arrow). (B) Expression of IL12 after in vitro transfection of 4T1 cells with control,
wtIL12, and peptide-IL12 (n=3) and (C) induction of IFNγ from splenocytes after
transfer of condition medium containing Control, wtIL-12, or peptide-IL12 gene
products. (D) IL12 accumulation in tumor-bearing IL12-/- mice treated with CHPIL12 or wtIL12 determined via an IL12p70 ELISA. Columns represent the
wtIL12-normalized level of IL12/protein (pg/mg) in tumor per IL12/protein
(pg/mg) in kidneys (green) and livers (blue) and IL12 pg/mL serum (orange, n=4).
Error bars represent s.e.m. (* represent p<0.05 compared to all groups). CMV,
Cytomegalovirus promoter; IVS, intron; SEAP, SEAP-coding sequence; STOP,
Stop codon; pA, bovine growth hormone polyadenylation signal; wt, wild-type
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CHP-IL12 Fusion Gene Therapy Increases Inhibition of Primary and Metastatic Tumor
Growth and Extends Survival. Balb/c mice bearing 4T1 or CT26 tumors and C3H mice
bearing SCCVII tumors were treated via i.m. EP with empty (Control), wild type IL-12
(wtIL12), and CHP-IL12 (CHP-IL12) fusion gene plasmid DNA. The treatment was repeated 10
days later. In the highly aggressive syngeneic 4T1 model, CHP-IL12 gene therapy, compared to
wtIL12 gene therapy, slowed tumor growth by 33%, while both wtIL12 and CHP-IL12 treated
tumors were less voluminous than control DNA treated mice (Fig. 3.3A). Likewise, CHP-IL12

Figure 3.3. Inhibition or regression of primary tumor growth, decrease in metastatic
tumor incidence, and increase in survival time by systemic delivery of CHP-IL12
plasmid DNA. (A) Tumor growth following treatments with CHP-IL12, wtIL12, and control
plasmid DNA in 4T1 tumor-bearing balb/c mice (n=5; * represents p<0.05 at day 30 and
p<0.001 from day 33 until day 42 compared to wtIL12 plasmid DNA and p<0.01 at day 21
and p<0.001 from day 24 to day 33 compared to control plasmid DNA). (B) Metastatic
nodules in the lungs of mice (n=5) treated as in A and sacrificed 17 days after the second
treatment (* represents p<0.05 compared to wtIL12 plasmid DNA; # represents p<0.001
compared to control plasmid DNA). (C) Kaplan-Meier survival analysis of the same mice
treated in A (* represents p<0.05 compared to wtIL12 plasmid DNA; # represents p<0.001
compared to control plasmid DNA). (D) Tumor growth following treatments as in A in
SCCVII tumor-bearing C3H mice (n=5; * represents p<0.05 on days 17 and 20 compared to
wtIL12 plasmid DNA and control plasmid DNA). (E) Kaplan-Meier survival analysis of the
same mice treated in D (* represents p<0.05 compared to wtIL12 and control plasmid DNA).
(F) Treatments as in A in CT26 tumor-bearing balb/c mice (n=5; * represents p<0.05
compared to wtIL12 plasmid DNA, n=4, on day 25, and control plasmid DNA, n=3, on days
19 through 25). Black arrows represent treatments, and error bars represent s.e.m.

68

treatments extended survival further than wtIL12 and Control (Fig. 3.3C). In the same tumor
model and treatment regimen, CHP-IL12 gene therapy reduced by half the number of
spontaneous metastatic nodules in the lungs compared to wtIL12 (Fig. 3.3B). Similarly, in the
SCCVII model CHP-IL12 improved tumor growth inhibition by 50% compared to wtIL12 (Fig.
3.3D) and extended survival of mice compared to both Control and wtIL12 (Fig. 3.3E).
In a third syngeneic model, CT26, CHP-IL12 treatments inhibited tumor volumes starting
only a few days after one treatment, and tumors began to regress after the second treatment (Fig.
3.3F). After day 25, tumors in both wtIL12 and CHP-IL12 treated mice began to be eradicated.
By day 55, 100% of mice treated with CHP-IL12 were tumor-free while only 75% of wtIL12
treated mice were tumor-free.
The CHP-IL12 treatments increased the immune response to the tumor cells. To
understand the mechanism by which CHP-IL12 boosts inhibition of tumor growth as compared
to wtIL12, both CTL activity and tumor microenvironment immune cell profiling were analyzed.
The rationale is that intratumoral injection, associated with a high level of IL12 in tumors,
boosted anti-tumor immune responses as compared to i.m. injection of IL12 plasmid DNA,
which is associated with a very low level of IL12 in tumors [121]. Treatment with CHP-IL12
increased the number of the tumor-infiltrating mature dendritic cells (DC) in the tumor
environment as determined by FACS for CD11c+/CD80hi expression (Fig. 3.4A). Tumors from
wtIL12 treated mice contained 76.9% mature DC, an increase from 73.7% in control treated
mice. This population in CHP-IL12 treated mice was even higher at 82.3% (Fig. 3.4A). In
agreement with this increase in mature DC in tumors, tumor-specific CTL activity was increased
with CHP-IL12 treated mice compared to wtIL12 treated mice (Fig. 3.4B). Furthermore, CHPIL12 treatments did not cause any further increase in serum IFNγ levels, so these immune
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Figure 3.4. Increased antitumor immune response by CHP-IL12 fusion gene treatments.
(a) FACS analysis of tumor infiltrating cells isolated from SCCVII tumors from C3H mice
treated as described in Fig. 5 collected 7 days after the second treatment. The top right
quadrant of the colored dot plot representation of cells gated for CD11c+ represents activated
DC (CD80hi). (b) Tumor-specific CTL activity from wtIL12 and CHP-IL12 fusion gene
plasmid DNA treated mice bearing orthotopic EMT6 tumors collected (* represents p<0.05).
(c) Serum IFNγ levels from 4T1-tumor bearing Balb/c 3 days after treatments with CHPIL12, wtIL12, and control plasmid. Error bars represent s.e.m.
responses are not the result of widespread IL12 activity (Fig. 3.4C). These results suggest that
CHP-IL12 improves the anti-tumor immune response of effector cells in the tumor
microenvironment.
CHP Homes to Vimentin Expressed in the Tumor Environment. CHP-biotin was used to
isolate the CHP receptor from a pool of cell-surface receptor proteins isolated from SCCVII
cells. Mass spectrometry of the isolated protein (Fig. 3.5A, white arrow) identified this protein as
vimentin. To validate this receptor, CHP-biotin was added to wells of a polystyrene plate that
were coated with coating buffer only, GST, or recombinant Vimentin-GST. Indeed, CHP
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interacts with vimentin as the vimentin-coated wells retained a significantly higher level of HRP
activity (Fig. 3.5B).
To determine the levels of vimentin expression in normal tissues versus tumors, tissue
lysates from an SCCVII tumor, heart, lung, liver, kidney, spleen, and serum from a C3H mouse
were probed for vimentin expression via western blot analysis (WB). Very low levels of

Figure 3.5. Identification of CHP interacting protein: vimentin. (A) SDS-PAGE
analysis of potential receptors for CHP isolated via affinity chromatography of a pool of
cell-surface proteins isolated from SCCVII cells. The only distinct band (white arrow) was
located in the second fraction, and mass spectrometry identified this band as vimentin. (B)
Interaction of CHP-biotin with recombinant vimentin-GST (Vimentin), GST, and coating
buffer only (Control) coated wells of a polystyrene plate (n=6; * represents p<0.001
compared to both GST and Control, errors bars represent s.e.m.). (C) Western blot analysis
of vimentin expression in an SCCVII tumor (1) and heart (2), lung (3), liver (4), kidney (5),
spleen (6), and serum (7) from SCCVII-tumor bearing C3H mice. (D) Western blot analysis
of vimentin expression in in vitro and ex vivo tumor samples. (E) Accumulation of peptidebiotin in syngeneic SCCVII tumor bearing C3H mice following i.v. injection of either
Control-biotin (top left and right) or CHP-biotin (bottom left and right) without (top and
bottom left) or with (top and bottom right) depletion of vimentin with a co-injection of
purified polyclonal goat anti-vimentin (100 µg) in the same i.v. injection as the peptidebiotin.
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vimentin were detected in the heart, liver, kidney, spleen, and serum (Fig. 3.5C, lanes 2 and 4
through 7) while high levels of vimentin were detected in the tumor and lung (Fig. 3.5C, lanes 1
and 3). Similarly, analysis of vimentin expression in SCCVII, CT26, 4T1, and B16F10
(melanoma cell line derived from C57Bl/6 mice) tumor cell lines and ex vivo tumor tissues
shows that all these tumor cell lines and their respective tumor models express vimentin (Fig.
3.5D), which explains the universal tumor homing property as illustrated in Fig. 3.1.
To determine that vimentin is the receptor protein interacting with CHP which is
responsible for tumor homing, we performed tail vein injections of Control-biotin and CHPbiotin with or without blocking vimentin using purified polyclonal goat anti-vimentin in SCCVII
tumor-bearing C3H mice. As expected, injection of Control-biotin with or without anti-vimentin
did not result in any accumulation of peptide in the tumor (Fig. 5e, top left and top right, 1.8 ±
0.37 with anti-vimentin and 2.6 ± 0.51 without anti-vimentin, n=5). However, CHP-biotin did
accrue in the tumor environment (Fig. 5e, bottom left, 19.6 ± 1.3 positive per field, n=5,
p<0.0001 compared to all other groups), but co-administration with anti-vimentin almost
completely inhibited the tumor targeting ability of CHP (Fig. 5e, bottom right, 1.2 ± 0.58
positive per field, n=5).
CHP-IL12 Reduces the Level of Toxic Lesions in the Liver. IL12 induces liver toxicity
(unpublished data) and it was our expectation that the tumor-homing CHP-IL12 may reduce the
toxicity. To test this hypothesis, SCCVII tumor-bearing C3H mice were treated with two
treatments of 1 µg (2 x 1 µg), 2 µg (2 x 2 µg), or 10 µg (2 x 10 µg) or three treatments of 2 µg (3
x 2 µg) of wtIL12 or CHP-IL12, and mice were sacrificed on days 1, 3, and 30 after the final
treatment. At low levels of plasmid DNA administration, 2 x 1 µg and 2 x 2 µg, there were no
differences between wtIL-12 and CHP-IL12 treatments; however, at the therapeutic level, 2 x 10
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µg, and the triple treatment, 3 x 2 µg, CHPIL12 treatments caused toxic lesions in only
one mouse while wtIL12 treatments had
significantly higher numbers (Fig. 3.6A).
Serum chemistry profiles of these mice
revealed that there were no differences
between any treatment, regimen, or time
points, and all levels for the hallmarks of
toxicity, such as Alanine Transaminase,
were normal (Fig. 3.6D).
Figure 3.6. Decreased liver toxicity of IL12
treatments with CHP-IL12. (A) Number of
SCCVII tumor-bearing C3H mice with toxic
lesions on the liver following two treatments of
1 µg (2 x 1 µg), 2 µg (2 x 2 µg), or 10 µg (2 x
10 µg) or three treatments of 2 µg (3 x 2 µg) of
wtIL12 or CHP-IL12 (n=12). (B)
Representative image of a normal liver area.
(C) Representative image of a toxic lesion.
Scale bar represents 50 µm in B and C. (D)
Levels of Alanine Transaminase (ALT), a key
indicator of liver function, for both plasmid
DNA treatments at all DNA levels and time
points.

Discussion
Tumor targeting can be achieved via
the screening of various libraries to select
tumor-targeted peptides, DNA/RNA
aptamers, antibodies, etc; however, the only
mechanism that can be used for homing
gene products from systemically injected
genes will be tumor-targeted mini-peptide

encoding DNA. These peptides are tiny which eliminates the concern of immunogenicity
(Appendix C) and reduces the effect on the biological function of the gene product, though some
minipeptides may boost or inhibit gene function [135]. The tiny peptide encoding DNA
sequences can be easily fused with any therapeutic gene. Finally, these peptides can complement
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existing tumor targeting approaches such as transcriptional targeting [122], translational
targeting [136], and targeted delivery [117-120].
In this study, we have identified a 7 amino acid targeted peptide, CHP. In this gene
therapy method, CHP is superior to the known cyclic tumor-homing peptides such as CNGRC
and RGD4C (Fig. 3.1), which rely on disulfide bonds to maintain the structure of the targeting
peptides [137, 138]. This linear structure may decrease the effect of the peptide on the activity of
the fusion protein and vice versa.
Other tumor targeting peptides can deliver small molecules with only one copy for each
small-molecule payload but require multiple copies of the peptide to target larger molecules such
as a full length cytokine [139]. In this study, we demonstrate that fusion of a single copy of CHP
encoding DNA can boost the accumulation of IL12 in tumors, suggesting one copy of CHP is
sufficient to carry one copy of IL12 to the tumor site. Of course, increasing the number of CHP
peptides per molecule may also increase the targeting efficiency.
Currently, most tumor-targeting strategies are based on extremely specific interactions,
and the ability to target the tumor environment is constrained to a single cell type or specific type
of tumor. We have shown that CHP can increase the efficacy of IL12 gene therapy to inhibit
tumor growth in the three tumor cell lines, breast adenocarcinoma, squamous cell carcinoma, and
colon carcinoma, and in two different mouse strains (Fig. 3.1). Subsequently, CHP-IL12 extends
survival more than wtIL12 treatments in both the breast adenocarcinoma and squamous cell
carcinoma (Fig. 3.3C,E). Similarly, CHP-IL12 treatments inhibit the development of
spontaneous lung metastasis, which is the primary killer of cancer patients (Fig. 3.3B). This
increase in antitumor response is associated with increases in both tumor-specific CTL activity
(Fig. 3.4) and IL12 accumulation in tumors (Fig. 3.2D). This result is in agreement with the
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result that intratumoral delivery of IL12 yields better anti-tumor efficacy than systemic delivery
[121]. The discovery of CHP permits us to use systemic delivery to target IL12 to tumors
without the need of intratumoral delivery, which is not realistic for treating internal tumors,
metastatic tumors, and residual tumor cells after standard therapy. In this regard, this peptide will
be extremely valuable, and further study is warranted.
We were able to identify a receptor for CHP as vimentin (Fig. 3.5), an intermediate
filament protein conventionally regarded as an intracellular structural protein in cells of
mesenchymal origin such as fibroblasts, chondrocytes, and macrophages [129]. Vimentin
expression has been reported to be increased in several tumor models, including human prostate,
colon [131], hepatocellular [130], and gemcitabine-resistant pancreatic cancers [133], and the
tumor stromal cells in human colorectal tumors [132]. The upregulation of vimentin is associated
with the epithelial-to-mesenchymal transition (EMT), which is important for motility as well as
metastasis in several tumors.
Though vimentin is upregulated in tumors, two remaining questions are how the CHP
targets an intracellular receptor and how the peptide avoids targeting lungs where vimentin is
also expressed. These questions were perfectly addressed recently by the discovery that vimentin
is expressed on the cell surface of tumor cells [140] and epithelial cells during angiogenesis
[141]. Additionally, some human tumor-initiating cells remaining after treatment overexpress
vimentin on the tumor cell surface [142]. Another important aspect of vimentin is the conserved
sequences among mouse, rat, dog, and humans [143]. This information along with the T/S SEAP
accumulation in the xenogeneic human tumor model (Fig. 3.1B) strongly suggests that CHP
targeting will crossover to human treatments.
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We also confirmed that vimentin is expressed at very low levels in the heart, liver,
kidney, spleen, and serum of C3H mice, yet it is highly expressed in lung tissue. Since most
general expression of vimentin is intracellular [129, 144, 145], this expression should not be a
target of CHP. As seen in Appendix B, there was no accumulation of CHP-biotin in the lung
sections which supports this notion. Conversely, vimentin is highly expressed in SCCVII tumors
in C3H mice, and CHP-biotin did accumulate in the SCCVII tumors (Fig. 3.2). Likewise, the
tumor cells and corresponding syngeneic tumors both express detectable levels of vimentin.
A potential problem with using CHP for targeting immunomodulatory agents is the
cellular fate of the surface-bound peptide and its payload. Ise et al. have recently described the
internalization of vimentin-bound ligands which could block the ability of the IL12 to stimulate
an anti-tumor immune response [146]. According to their studies, the vimentin-bound ligands are
still located on the cell surface after 2 h. The half-life of circulating IL-12 is between 2.5 and 3.3
h [147]; therefore, internalization would not affect the IL-12 activity. Further, if CHP is
eventually internalized by the tumor cells, then CHP would also be a potent targeting modality
for using intracellular antitumor agents, which is an area that requires further investigation.
We have developed a fully functional tumor targeting IL12 gene construct that can be
delivered systemically for treating distally located neoplastic diseases. Inserting peptideencoding sequences directly prior to the stop codon in the p40 gene of an IL12 plasmid did not
interfere with transcription, translation, post-translational modifications, or therapeutic
functionality of the IL12 gene product (Fig. 3.2). Also, CHP maintains its tumor-targeting ability
as seen in IL12-/- mice (Fig. 3.2) and can increase the therapeutic efficacy of systemic IL12 genetherapy treatments (Fig. 3.3) while decreasing liver toxicity (Fig. 3.6). Future studies will
include investigating the fate of vimentin-bound CHP, methods to increase the targeting
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efficiency, the potential for CHP to target other modalities, and the efficacy of other CHPantitumor fusion gene constructs.
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Chapter 4
Concluding Remarks
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Overall Summary of Findings
As discussed in Chapter 1, tumor-targeted cytokine therapies are poised to be a major
breakthrough for immunotherapies as they have the potential to increase the level of intratumoral
cytokines while lowering the systemic levels leading to higher efficacy and lower toxicity [148151]. The major problems that face these therapies are the methods of administration and the
availability of targets. Specifically, metastatic and residual tumor cells are nearly impossible to
treat directly until they are established and invasive, thereby necessitating invasive procedures or
systemic treatments. To solve these problems, new targeted-cytokine treatment strategies are
needed.
In Chapter 2, we examined the effects of inserting mini-peptide coding sequences into a
secreted alkaline phosphatase (SEAP) reporter gene plasmid DNA. In vitro transfection of
several mini-peptide SEAP plasmid DNAs in several different normal and cancer cell lines
revealed dramatic changes in the activity of the gene products which were dependent on the
peptide and not the cell type. Specifically, we showed that the peptide CWDDWLC significantly
improved the activity of the SEAP enzyme. Removing the flanking Cys residues on this peptide
ablated this activity increase, and inserting a Gly residue into the sequence (CWDDGWLC)
reduced the SEAP activity to nearly undetectable levels. The increased activity of the
CWDDWLC-SEAP enzyme also occurs following intramuscular transfection in a mouse model.
Surprisingly, western blot analyses showed that the increased SEAP activity was not due to an
increase in the amount of SEAP protein produced. These studies revealed the drastic effects that
inserting peptides could have on the activity of the SEAP enzyme, but the production of the gene
product was not altered. So, this peptide-SEAP system could be used to screen peptides for
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tumor-targeting capabilities, but the only way to correct for the activity modifications is to use
the ratio of activities seen in the different tissues.
As described in Chapter 3, we used the peptide-SEAP screening strategy to identify the
best peptide which can be used to target an in vivo produced product to the tumor environment.
In multiple tumor models including a human xenogeneic model, the peptide VNTANST
(referred to as the Comprehensive Carcinoma Homing Peptide, CHP) significantly increased
accumulation of SEAP in the tumor environment as evidence by the increased Tumor/Serum
SEAP levels. Then, we created a tumor-targeted IL12 fusion gene construct (CHP-IL12) which
maintained both the biological activity of the IL12 and the targeting ability of CHP. Systemic
treatments with CHP-IL12 plasmid DNA in three syngeneic tumor models resulted in inhibition
of primary tumor growth, and survival was extended in two of the models compared to wtIL12
gene treatments. Additionally, CHP-IL12 treatments decreased the development of metastasis.
The improved efficacy of these treatments resulted from an increase in the level of mature DC in
the tumor environment and elicited more potent tumor-specific cytotoxicity by CTL.
Additionally, these treatments reduced systemic toxicity and resulted in significantly less lesions
in the livers compared to wtIL12 plasmid DNA treatments. Affinity chromatography and mass
spectrometry identified the target for CHP as vimentin. These results show the potential for using
these mini-peptides for targeting in vivo produced gene products to tumors.
Significance of Research
Improving cancer treatments is necessary to combat the incessant presence of neoplastic
diseases and to improve the quality of life of patients undergoing these treatments.
Immunomodulatory therapy is an encouraging field that can offer increased efficacy, decreased
toxicity, and improved quality of life, and cytokines hold great potential for these therapies. To
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date, IL-2 and IFNα are the only cytokines approved for cancer therapies, but IL12 and GM-CSF
are on the precipice of becoming the next possibilities. Unfortunately, the toxicities that are
associated with these treatments, especially IL-12, continue to hinder their translation into
clinical applications [152]. The keys to improving IL12 therapy and reducing these toxicities are
increasing the level of intratumoral IL12 and decreasing systemic IL12 [150]. Recombinant
versions of IL-12, such as mrIL12vp [148] and L19-IL12 [149], and IL-12 plasmid loaded viral
vectors, such as AdRGD-IL12 [151], have been developed to target to the tumor, yet none have
been able to overcome the low therapeutic efficacy and high toxicity. A novel method to reach
these goals is a non-viral tumor targeted cytokine therapy.
Vital to making this therapy work is identifying a modality that can be produced in vivo
from plasmid DNA. Of the current tumor-targeting modalities, mini-peptides which specifically
home to receptors uniquely located in the tumor environment are the only method that can be
used for this purpose; however, until now no peptides have been shown to have the ability to be
transduced and produced at a site distal from the tumor and then target to the tumor environment.
To this end, the reporter-gene mediated screening strategy developed as described in Chapter 2
was used to identify CHP, a peptide with these characteristics.
Also, using this strategy to serially screen peptides in multiple tumors can identify
peptides that target tumor-specific modalities in several types of tumors. In this case, vimentin is
the target which we were able to exploit. Other methods, such as Witheferin A and anti-vimentin
antibodies have used vimentin as a target for therapy [153, 154]; however, this CHP-mediated
tumor targeting gene therapy is the first non-recombinant protein method used. Vimentin is an
especially appropriate target to use for tumor-homing strategies because it is expressed on the
cell surface of several human tumors [155-158], chemotherapy-resistant tumors [159], tumor-
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initiating cells [160], and epithelial cells in angiogenic vessels [161]. Additionally, the results
seen in these studies are important because the sequence of vimentin is conserved between mice
and humans [162]. So, using CHP as a targeting peptide for clinical applications is promising.
Using CHP, we have shown that systemic delivery of a tumor-targeted cytokine gene can
be used for treating tumors. After systemic delivery, the gene product homes to the tumor
environment, increases the anti-tumor immune response, and decreases the toxic side effects.
Further, these results were seen with only two treatments separated by 10 days. The recombinant
targeted and viral gene treatments require several treatments, usually administered daily or every
other day for up to 90 days to see similar responses [163, 164]. In addition to the improved
quality of life for patients undergoing these treatments, the cost of producing microgram levels
of plasmid DNA versus the milligram levels of recombinant proteins will be beneficial to the
patients, insurance companies, and tax-payers.
Future Directions
The potential for using CHP to target gene products to tumors is clearly evidenced by the
results presented here; however, the capability of CHP to target other payloads is still unknown.
The CHP-biotin experiments described in Chapter 3 (Fig. 3.2) prove that the targeting capacity
of CHP is not strictly for gene products. So, testing the size and biological limits of what CHP
can carry is necessary. Conjugating CHP to chemotherapeutic drugs, tyrosine kinase inhibitors,
siRNA, and any other anticancer medication can be potentially beneficial in the same manner
that improved the efficacy and reduced toxicity of systemic IL12 gene treatments. Truly, this is
an exciting peptide which demands further investigation.
Similarly, the mini-peptide tumor-targeted cytokine approach has many avenues that
need to be explored. CHP was a peptide identified out of a relatively small subset of known
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tissue- and tumor-targeting peptides [165]; therefore, the possibility of identifying peptides with
similar multi-tumor targeting abilities that can target in vivo produced gene products is high.
Alternatively, identifying which cytokines can be used in this method is necessary. GM-CSF,
IL15 [153], and other cytokines that are already being explored for cancer treatments can
potentially be used, and their efficacy in these treatments will be tested. Furthermore, promising
results from combinatorial cytokine and chemotherapeutic treatments [166] could also be
improved by potentially using peptide-cytokine gene therapies in combination with peptidechemotherapy systemic treatments. In conclusion, the results described in this work are merely
the beginning of what seems to be a promising new approach for improving cancer treatments.
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Appendix A.
Mascot Search Results from Mass Spectrometry Analysis
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Appendix B.
Lack of CHP-biotin Localization in Tissues

Sections from the hearts, lungs, livers, kidneys, and spleens from the same mice in
Figure 3.2 were counterstained with eosin only. Scale bar represents 100 µm.

89

Appendix C.
Lack of Immunogenecity of CHP

The level of CHP-specific IgG from EMT6-tumor
bearing Balb/c mice treated with wtIL12 or CHPIL12 gene therapy as determined via binding to
wells of a microwell plate coated with coating
buffer only, control peptide or CHP peptide (n=3).
Error bars represent s.e.m.
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